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Abstract 
The p53 protein is a transcription factor with a well-known tumour suppressor 
activity, which is inactivated in most human cancers due to mutation or to the negative 
regulation by MDM2 and MDMX. Human cells encode two other p53-related proteins, 
p63 and p73, which can induce the transcription of p53 target genes or to have distinct 
physiological functions from p53 in cancer. Based on this, the pharmacological regulation 
of p53 family proteins has been considered a promising therapeutic strategy against 
cancer. However, the high complexity of the p53 family-pathway, particularly the 
simultaneous expression of several isoforms in a same mammalian cell, has hampered 
the knowledge of the biology and pharmacology of these proteins.  
To circumvent this issue, in the present work, the yeast Saccharomyces 
cerevisiae (without orthologues of p53 family proteins) was used as a simplified cellular 
system for an independent analysis of individual p53 family proteins. Particularly, using 
a previously developed yeast-based p53-MDM2 screening assay, -mangostin and 
gambogic acid, two xanthones with well-known antitumor properties, were identified as 
potential inhibitors of the p53-MDM2 interaction. In a previous study, this yeast-based 
assay also led to the identification of potential p53 activators with a flavonoid scaffold, 
which molecular mechanism was studied, in this work, in human colon tumour cell lines 
with and without p53. The tested flavonoids exhibited potent growth inhibitory activities 
against the two human tumour cells, suggesting that besides p53 other molecular targets 
may be involved in their activities. Moreover, with the yeast model, relevant data about 
the role of p53 family proteins on cell proliferation and death were revealed.  
Additionally, in this work, new yeast assays were developed, which may 
represent relevant tools for future studies of p53 family proteins, particularly for the 
identification of new therapeutic opportunities against cancer. In fact, the inhibitory effect 
of MDMX on p53 was reproduced in yeast, for the first time, which led to the development 
of a yeast-based assay for the screening of p53-MDMX interaction inhibitors. Moreover, 
with the identification of ACT1 as a possible yeast endogenous p53 target gene, this 
work opened the way to a new simplified yeast p53 transactivation assay, which may be 
used for the analysis of the p53 transcriptional activity, instead of the traditional artificial 
yeast transactivation reporter assays.  
As a whole, the yeast research performed in this thesis confirmed the enormous 
potential of this cell model towards the study of human proteins. Additionally, with this 
work, new ways were opened and several relevant questions were raised in the p53 
family research field.  
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Resumo 
A proteína p53 é um fator de transcrição com atividade supressora tumoral, a qual se 
encontra inativada na maioria dos tumores humanos, devido a mutações ou à inibição pelas 
proteínas MDM2 e MDMX. As células humanas codificam duas proteínas relacionadas com 
a p53, p63 e p73, as quais podem induzir a transcrição de genes-alvo da p53, ou 
desempenhar, no cancro, funções fisiológicas distintas das da p53. Assim, a modulação 
farmacológica das proteínas da família p53 tem sido considerada uma estratégia promissora 
no tratamento do cancro. Contudo, a complexidade das vias de sinalização das proteínas da 
família p53, em particular a expressão de várias isoformas na mesma célula, tem dificultado 
a compreensão das propriedades biológicas e farmacológicas destas proteínas.  
Para contornar esta limitação, neste trabalho, utilizou-se a levedura Saccharomyces 
cerevisiae (sem ortólogos das proteínas da família p53), como um modelo celular simplificado 
para uma análise individual das proteínas da família p53. Em particular, utilizando-se um 
modelo previamente estabelecido pelo grupo para a pesquisa de moduladores da interação 
p53-MDM2, identificou-se a α-mangostina e o ácido gambógico, duas xantonas com 
propriedades anti-tumorais, como potenciais inibidores da interação p53-MDM2. 
Anteriormente, este modelo permitiu a identificação de flavonóides como potenciais 
ativadores da p53, cujo mecanismo molecular foi estudado, neste trabalho, em linhas 
tumorais de carcinoma do cólon, com e sem p53. Os flavonóides inibiram o crescimento de 
ambas as linhas tumorais com uma potência semelhante, sugerindo o envolvimento de outros 
alvos celulares para além da p53. Além disso, com o modelo da levedura, são revelados 
conhecimentos importantes acerca do papel das proteínas da família p53 na proliferação e 
morte celular.  
Adicionalmente, neste trabalho, foram implementados novos modelos de levedura, 
que se revelam muito promissores no estudo das proteínas da família p53, em particular na 
identificação de novas oportunidades terapêuticas contra o cancro. De facto, com a 
reprodução do efeito inibitório da MDMX na p53, pela primeira vez, em levedura, 
implementou-se um modelo de pesquisa de inibidores da interação p53-MDMX. Além disso, 
a identificação do gene ACT1 de levedura como um possível alvo da p53 poderá permitir a 
implementação de um ensaio simplificado para o estudo da atividade transcricional da p53, 
em substituição dos artificiais atualmente disponíveis. 
No geral, a investigação desenvolvida no âmbito desta tese confirmou o enorme 
potencial da levedura como um organismo modelo para o estudo de proteínas humanas. 
Além disso, com este trabalho, novos caminhos e diversas questões foram levantadas na 
área de investigação das proteínas da família p53. 
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1. Introduction 
1.1. The p53 family of proteins 
The p53 protein was discovered more than 30 years ago as a protein interacting 
with the oncogenic T antigen from SV40 virus (Lane and Crawford, 1979; Linzer and 
Levine, 1979). This well-known tumour suppressor protein acts as an inducible 
sequence-specific DNA-binding transcription factor, playing a fundamental role in the 
maintenance of genomic integrity and normal cell growth. When activated in response to 
stress stimuli, such as DNA damage, oncogene activation, hypoxia or nutrient 
deprivation, p53 triggers a cascade of cellular responses in order to prevent the 
replication of damaged DNA or the proliferation of genetically altered cells that could lead 
to tumour formation. Due to its tumour preventive activity, p53 has been called “the 
guardian of the genome” (Lane, 1992; Wei et al., 2012).  
Almost 20 years after the discovery of p53, two TP53-related genes, TP63 and 
TP73 (encoding p63 and p73, respectively), were identified (Kaghad et al., 1997; Yang 
et al., 1998). Although p53 was the first member of this group of proteins to be 
discovered, mainly due to its essential role in carcinogenesis, phylogenetic studies 
suggested that the p53 family derived from the triplication of a p63/p73-like ancestral 
gene was likely involved in the preservation of genomic stability in germ cells (Dotsch et 
al., 2010; Petre-Lazar et al., 2007; Rutkowski et al., 2010). p53, p63 and p73 share 
remarkable structural similarities, which led to the initial speculation that these proteins 
might have identical functions. However, accumulated data have suggested that unlike 
p53, p63 and p73 have a major role in the regulation of embryonic development 
[reviewed in (Deyoung and Ellisen, 2007)]. 
An increasing number of studies have also suggested that p53 family proteins 
regulate many vital biological processes, and alterations of their activities may often 
underlie mechanisms of malignant transformation and even affect tumour response to 
therapy. In fact, p53 inactivation promotes tumourigenesis by enhancing tumour cell 
growth and resistance to chemotherapy and radiotherapy. p53 is inactivated in the vast 
majority of human tumours, and TP53 is the most mutated gene in human cancer 
(Hollstein et al., 1996; Hollstein et al., 1991). Although mutations in the TP63 and TP73 
genes are less common, the p63 and p73 proteins appear to also play important roles in 
many human tumours through both p53-dependent and independent pathways. The 
contribution of p63 and p73 to tumourigenesis is complex since multiple isoforms of each 
protein are simultaneously expressed in human cells (Kovalev et al., 1998). 
4 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
1.1.1. Structural organization 
The TP53, TP63 and TP73 genes are located on chromosomes 17p13.1, 
3q27-29 and 1p36.2-3, respectively (Wei et al., 2012). Through activation of different 
promoters and alternative splicing, each gene gives rise to multiple protein isoforms. The 
specific functions of each isoform are still not clearly established. The TP63 and TP73 
genes have two promoters, generating proteins that can be categorized into two main 
groups (Fig. 1): i) proteins containing an N-terminal acidic transactivation domain (TAD), 
termed TA isoforms, resulting from the P1 promoter (located upstream of exon 1) and ii) 
N-terminally truncated proteins lacking the TAD, called ΔN isoforms, arising from 
transcription from the P2 promoter (located between exons 3 and 4). In addition, in the 
case of p73, other ΔN isoforms have been described (ΔN’p73, ΔEx2p73 and ΔEx2-3p73) 
to be produced through P1 activation and alternative splicing at the 5’ end (Sayan et al., 
2007; Vilgelm et al., 2008; Yang et al., 1998). Regarding the TP53 gene, it includes an 
additional promoter P1’ (located upstream of exon 1), which gives rise to proteins 
containing the full TAD, while the transcription initiated in the P1 promoter (located within 
exon 1) produces proteins lacking the first 40 amino acid residues (Δ40p53). On the 
other hand, proteins produced through activation of the P2 promoter (between exons 4 
and 5) lack the first 133 amino acids (Δ133p53) (Wei et al., 2012).  
Besides the activation of different promoters, additional diversity is generated by 
alternative splicing at the 3’ end, which gives rise to splice variants traditionally named 
with letters from the Greek alphabet. Eight splice variants have been described for p53 
(α, β, γ, δ, ε, ζ, Δp53 and ΔE6), five for p63 (α, β, γ, δ and ε) and nine for p73 (α, β, γ, δ, 
ε, θ, ζ, η and η1) (Fig. 1). The transactivation and apoptotic potential of p63 and p73 (TA 
isoforms) vary greatly depending on the isoform. However, they are generally considered 
to be less efficient than p53. p63γ and p73γ are the isoforms that most closely resemble 
full-length p53. In fact, p63γ has been shown to be as potent as p53 regarding the 
induction of gene transcription and apoptosis, while the most potent p73 isoform appears 
to be p73β. Little is known about the functions of the remainder isoforms, since most 
studies have been focused on the α, β and γ isoforms [reviewed in (Allocati et al., 2012)]. 
Alternative splicing combined with alternative promoter usage results in the 
production of a large number of isoforms. Theoretically, the TP53 gene can produce at 
least 20 isoforms, while TP63 can produce at least 10, and TP73 more than 40, although 
not all have been experimentally confirmed [reviewed in (Wei et al., 2012)]. 
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Fig. 1 – Architectures of human TP53, TP73, and TP63 genes. Transcription of p53 family genes is controlled by two 
promoters, P1 and P2. P2 gives rise to N-terminally truncated isoforms, lacking all or part of the TAD. TP53 possesses 
an additional promoter. Alternative splicing at the C-terminus leads to the generation of a variety of different isoforms of 
each protein [adapted from (Wei et al., 2012)]. 
 
 
 
All p53 family proteins possess three conserved structural domains: a 
DNA-binding domain (DBD), an oligomerization domain (OD) involved in the 
tetramerization of these proteins, required for their activity, and a transactivation domain 
(TAD) [Fig. 2; reviewed in (Allocati et al., 2012)]. The DBD presents the highest degree 
of homology among the three members, with over 60% amino acid identity between p53 
and p63/p73, and about 85% amino acid identity between p63 and p73. This suggests a 
central role for the transcriptional activity among the range of functions attributed to p53 
family proteins. Regarding the OD, the amino acid identity between p53 and p63/p73 is 
only about 30%, perhaps explaining why p63 and p73 are unable to form 
hetero-oligomeric complexes with wild-type (wt) p53. On the other hand, the ODs 
homology between p63 and p73 is approximately 60%. Therefore, p63 and p73 are able 
to form heterotetramers, although with less efficiency than homotetramers (Davison et 
al., 1999). p63 and p73 have an additional domain at the C-terminus termed sterile-alpha 
motif (SAM) (Fig. 2), which is responsible for protein-protein interactions. This type of 
6 FCUP 
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motif can be found in a wide range of proteins involved in developmental regulation, also 
being implicated in transcriptional repression and in lipid membrane binding (Thanos and 
Bowie, 1999). In the alpha isoforms of p63 and p73, an additional post-SAM region has 
been identified and designated transactivational inhibitory domain (TID). TID is thought 
to be involved in the inhibition of the transactivating function of these proteins through 
intra- or intermolecular associations with the TAD. In fact, the p63 and p73 proteins 
appear to be less potent in transactivation and apoptosis induction, and their potency 
can be restored through deletion of the TID (Serber et al., 2002; Vilgelm et al., 2008). 
 
 
 
 
Fig. 2 – Schematic representation of p53 family protein structure. p53 family proteins possess a transactivation 
domain (TAD), a DNA-binding domain (DBD) and an oligomerization domain (OD). p63 and p73 have an additional domain 
at the C-terminal, named sterile-alpha domain (SAM) [adapted from (Allocati et al., 2012)]. 
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1.1.2. Molecular targets and signalling pathways 
Low levels of p53 can be found in unstressed cells due to the constant proteasomal 
degradation of this protein (Olsson et al., 2007). Upon exposure to a variety of stress signals, 
p53 undergoes post-translational modifications, which lead to its stabilization and activation. 
Under these conditions, p53 accumulates in the nucleus, where it transcriptionally regulates 
a large number of downstream genes involved in cell cycle and cell death, among other 
cellular processes. Most p53 functions result from its binding to specific DNA sequences, 
called p53-responsive elements (p53REs), and consequent transcriptional activation of 
target genes involved in key cellular processes. Nevertheless, it is widely recognized that 
p53 can also influence several cellular processes through transcription-independent 
mechanisms [reviewed in (Alsafadi et al., 2009)].  
Many functions attributed to p53 are shared by p63 and p73 (TA isoforms). This can 
be explained by the ability of these proteins to transactivate an overlapping array of target 
genes, since these proteins are able to bind to p53REs [reviewed in (Vilgelm et al., 2008)]. 
In fact, p63 and p73 have been shown to interact with p53REs in reporter assays. Chromatin 
immunoprecipitation experiments also demonstrated the ability of endogenous p63 and p73 
to bind to p53-regulated promoters (Costanzo et al., 2002; Perez et al., 2007; Tomkova et 
al., 2006). In contrast, the ΔN isoforms of p63 and p73, which lack the TAD, are usually 
described as having a dominant-negative effect on TA isoforms (Alsafadi et al., 2009). Two 
non-mutually exclusive mechanisms have been proposed to explain this dominant negative 
effect: promoter competition and heterocomplex formation (Nakagawa et al., 2002; Stiewe 
et al., 2002; Vilgelm et al., 2008; Zaika et al., 2002). In promoter competition, the ΔN isoforms 
would compete with the TA isoforms for their target gene promoters, thus preventing 
TA-mediated transcriptional activity. Heterocomplex formation could be explained by the 
presence of the same OD in ΔN isoforms, which allows the formation of transcriptionally 
inactive hetero-oligomers with TA variants. In a given cellular context, the net effects of p53 
family proteins are dependent on the TA/ΔN expression ratio. It has been described that 
both p53 and p73 can regulate the expression of ΔNp73 through direct activation of the P2 
promoter of p73 (Grob et al., 2001; Kartasheva et al., 2002). A p53 binding element has 
been identified within the P2 promoter of TP63, which allows p53 to induce the expression 
of ΔNp63 (Harmes et al., 2003). Therefore, auto-regulatory feedback loops are established 
for the fine control of the TA/ΔN expression ratio, and consequently of the expression levels 
of p53 family target genes. ΔN isoforms appear to integrate a feedback mechanism to 
prevent an exacerbated activity of TA isoforms. However, current data suggest that these 
isoforms may have other functions. In fact, both ΔNp63 and ΔNp73 appear to exert their own 
transcriptional activity, mediated by additional transactivation domains (Dohn et al., 2001; 
Liu et al., 2004; Wu et al., 2003). 
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Cell cycle 
One of the most important cellular processes regulated by p53 family proteins is 
the cell cycle. Cell cycle comprises four stages: Gap1 (G1; in which cells increase in 
size), synthesis (S; in which DNA replication occurs) and Gap2 (G2; in which cells 
continue to grow), collectively designated interphase, and the last phase, mitosis (M), 
corresponding to the nuclear division. Cell cycle checkpoints regulate the progression of 
cells through each stage of the cell cycle, in order to prevent the transmission of 
damaged genetic material to the daughter cells. There are four cell cycle checkpoints: 
G1/S, intra-S, G2/M and the spindle assembly checkpoint [reviewed in (Nurse, 2000)]. 
These cell cycle checkpoints are regulated by cyclin-dependent kinase complexes, 
which are protein complexes formed though association of an inactive catalytic subunit, 
cyclin-dependent kinase (Cdk), with a regulatory subunit, cyclin. Since Cdk levels are 
usually constant throughout the cell cycle, the regulation of cell cycle progression 
depends on variations of the levels of each cyclin (Morgan, 1995). In response to a 
variety of stress signals, the p53 family proteins can induce cell cycle arrest by inhibiting 
the G1/S or G2/M transitions (Fig. 3) [reviewed in (Harms et al., 2004)], as will be 
explained below. 
 
 
 
 
Fig. 3 – Regulation of the cell cycle by p53 family proteins.  p53 family proteins induce cell cycle arrest by inducing 
the expression of several proteins, resulting in the inhibition of the G1/S and G2/M transitions. [CAK: Cdk-activating kinase; 
Cdk: cyclin-dependent kinase; GADD45: growth arrest and DNA-damage inducible protein; PCBP4: poly(rC) binding 
protein 4; Rb: retinoblastoma protein). Adapted from (Harms et al., 2004)]. 
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During G1 phase, the expression of cyclin D is stimulated (Stevens and La Thangue, 
2003). This cyclin forms complexes with either Cdk4 or Cdk6, which can then target the 
retinoblastoma protein (Rb) for phosphorylation. Once phosphorylated, Rb releases the E2F 
transcription factor, which leads to the transcription of genes required for S-phase entry (Fig. 
3, left panel). One of the target genes of E2F is cyclin E which forms a complex with Cdk2, 
that phosphorylates and consequently inhibits Rb, leading to the establishment of a positive 
feedback loop (Koff et al., 1992; Weinberg, 1995; Zetterberg et al., 1995). In response to 
cellular stress (and probably to specific developmental signals), p53 family proteins induce 
the transcription of p21, a Cdk inhibitor that binds to cyclin E/Cdk2 and cyclin D/Cdk4/6 
complexes, thus preventing the G1/S transition (Chen et al., 1996; el-Deiry et al., 1993). 
Although p21 is the major effector of p53 family-mediated G1 arrest, there are other proteins 
involved in this process that are upregulated by p53, such as hCDC4b, a component of the 
Skp, Cullin, F-box containing ubiquitin ligase complex, that targets cyclin E for degradation, 
thus inhibiting the S-phase entry (Kimura et al., 2003). Interestingly, p57KIP, a Cdk inhibitor 
involved in the induction of G1 arrest, has been described as a unique target of p73 (Balint 
et al., 2002). 
Entry in mitotisis is regulated by the cyclin B1/Cdk1 complex, which is activated 
through the combined activity of Cdc25c phosphatase (which removes phosphate groups 
that compromise the activity of the complex) and Cdk activating kinase (CAK; which adds 
phosphate groups on specific points required for activation of the complex) (Kishimoto and 
Okumura, 1997) (Fig. 3, right panel). p21, a major transcriptional target of p53, participates 
in G2 arrest through association with the cyclin B1/Cdk1 complex and inhibition of its 
phosphorylation by CAK (Smits et al., 2000). The growth arrest and DNA damage inducible 
protein (GADD45) was the first identified p53-target gene. It binds to Cdk1 preventing its 
binding to cyclin B1, and, consequently, the formation of the protein complex necessary for 
mitotic entry, which results in G2 arrest (Zhan et al., 1999). p53 is also able to induce the 
expression of other proteins involved in G2 arrest, namely the poly(rC) binding protein 4 
(PCBP4; a RNA-binding protein), Reprimo (a highly glycosylated protein that is thought to 
play a role in cyclinB1/Cdk1 localization), and B99 (a protein with microtubule localization) 
(Ohki et al., 2000; Utrera et al., 1998; Zhu and Chen, 2000). The activity of the cyclin B1/Cdk1 
complex is also modulated by subcellular localization, since during interphase it is kept in 
the cytoplasm through nuclear export. Both p53 and p73 are able to induce the expression 
of 14-3-3σ, a scaffold protein involved in G2 arrest, by promotion of cyclinB1/Cdk1 nuclear 
export. Through this mechanism, 14-3-3σ inhibits the cyclinB1/Cdk1 complex, by physically 
separating it from its target proteins (Hermeking et al., 1997). In addition, p53 was reported 
to promote G2 arrest through repression of the expression of proteins essential for mitotic 
entry, namely Cdk1, cyclinB1 and Cdc25c (Krause et al., 2000; Taylor et al., 2001; Yun et 
al., 1999). 
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Apoptosis 
Apoptosis is a programmed cell death process characterized by nuclear 
condensation and fragmentation, mitochondrial swelling, and membrane blebbing. This 
type of cell death occurs without inflammation. There are two main apoptotic pathways: 
the extrinsic (or death receptor pathway) and the intrinsic (or mitochondrial pathway) 
(Fig. 4) [reviewed in (MacFarlane, 2003; Newmeyer and Ferguson-Miller, 2003)].  
Briefly, the extrinsic pathway consists on the activation of cell death receptors 
located at the plasma membrane, such as KILLER/DR5 and Fas. The activation of 
these receptors leads to their trimerization and consequent clustering of the 
intracellular death domain, which subsequently recruits the protein adaptor FADD 
(Fas-associated protein with death domain) through homotypic death domain 
interactions. The death effector domain of FADD then recruits caspase-8, forming the 
death-inducing signalling complex (DISC).  
On the other hand, the intrinsic pathway involves alterations of the mitochondrial 
membrane potential. These alterations can be caused by the translocation of Bcl-2 
family proteins to the mitochondria. Bax (Bcl-2 associated X protein) translocates from 
the cytosol to the inner mitochondrial membrane where it facilitates the release of 
cytochrome c (cyt c). Similarly, PUMA (p53 upregulated modulator of apoptosis) 
interacts with Bcl-2 and Bcl-xL, inducing the cyt c release from the mitochondrial 
membrane (Yu et al., 2001). Interestingly, Bid (BH3 interacting domain death agonist) 
appears to function as a bridge between the extrinsic and intrinsic pathways. It is 
cleaved by caspase-8, thus exposing an N-terminal glycine that is subsequently 
myristoylated. The modified Bid then translocates to the mitochondria, where it 
participates in the intrinsic apoptotic pathway (Li et al., 1998; Zha et al., 2000). Noxa 
has also been shown to localize to the mitochondria where it interacts with 
anti-apoptotic members of the Bcl-2 family, resulting in the efflux of cyt c (Seo et al., 
2003). Once released to the cytoplasm, cyt c combines with Apaf-1 (apoptosis 
protease-activating factor 1) and the initiator caspase-9, forming the apoptosome.  
Both these pathways result in the activation of executioner caspases 
(caspases-3, -6 and -7) which will then cleave nuclear and cytoskeletal structure 
proteins, leading to apoptosis.  
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Fig. 4 – Regulation of intrinsic and extrinsic apoptotic pathways by p53. p53 induces the expression of proteins 
involved in both the intrinsic and the extrinsic pathways of the apoptotic cell death. p53 can also induce apoptosis through 
a transcription-independent pathway, through its direct translocation to the mitochondria, where it interacts with members 
of the Bcl-2 family. The asterisks refer to p53 transcriptional activity. [Apaf-1: apoptotic protease activating factor 1; Bax: 
Bcl-2 associated X protein; Bid: BH3 (Bcl-2 homology domain 3) interacting domain death agonist; FADD: Fas-associated 
protein with death domain; mtCLIC: mitochondrial chloride intracellular channel; p53AIP: p53-regulated apoptosis inducing 
protein 1; PUMA: p53-upregulated modulator of apoptosis; TRAIL: TNF (tumour necrosis factor)-related 
apoptosis-inducing ligand. Adapted from (Ryan, 2011)]. 
 
 
 
The p53 protein is able to induce apoptosis through the extrinsic pathway by 
upregulating two cell death receptors, KILLER/DR5 and Fas, as well as the ligand for 
Fas, FasL (Fukazawa et al., 1999; Owen-Schaub et al., 1995; Takimoto and El-Deiry, 
2000). CASP8, the gene that encodes caspase-8, is another transcriptional target of p53 
(Liedtke et al., 2003).  
In addition, p53 family proteins may up-regulate several proteins involved in the 
intrinsic apoptotic pathway. These include pro-apoptotic proteins from the Bcl-2 family, 
such as Bax, Noxa, PUMA and Bid (Miyashita and Reed, 1995; Nakano and Vousden, 
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2001; Oda et al., 2000a; Sax et al., 2002). Furthermore, p53 is able to promote apoptosis 
through transcriptional repression of the anti-apoptotic members of the Bcl-2 family, 
namely Bcl-2 and Bcl-xL, which stabilize the mitochondrial membrane potential (Sugars 
et al., 2001). Both p53 and p73 induce the expression of p53AIP1 (p53-apoptosis 
inducing protein 1), which localizes to the mitochondria where it interacts with Bcl-2 to 
facilitate the release of cyt c and the consequent apoptosis induction through the intrinsic 
pathway (Costanzo et al., 2002; Oda et al., 2000b). p53 also upregulates mtCLIC/CLIC4 
(mitochondrial chloride intracellular channel), an organellular chloride channel protein 
that reduces mitochondrial membrane potential (Fernandez-Salas et al., 2002). 
Additionally, p53 induces the expression of intracellular regulators of the intrinsic 
apoptotic pathway, namely Apaf-1 and caspase-6 (Fortin et al., 2001; MacLachlan and 
El-Deiry, 2002).  
Besides its transcriptional function, accumulating data have shown that p53 itself 
can translocate to the mitochondria where it induces apoptosis through a 
transcription-independent mechanism (Manfredi, 2003). Haupt and colleagues (1995) 
described that a mutant variant of p53, which failed to upregulate gene expression, 
retained the ability to induce apoptosis, thus suggesting the existence of a 
transcription-independent mechanism of action of the p53 protein. Since then, it has 
been described that a fraction of p53 translocates to the mitochondria in tumour cells 
undergoing p53-dependent apoptosis (Marchenko et al., 2000). Furthermore, Mihara 
and colleagues (2003) have shown that targeting p53 to the mitochondria is sufficient for 
apoptosis induction, and have provided evidence that supports the formation of 
complexes between p53 and the anti-apoptotic proteins Bcl-2 and Bcl-xL. The formation 
of such complexes results in the release of the pro-apototic members of the Bcl-2 family, 
Bax and Bak (Bcl-2 antagonist/killer), and consequent permeabilization of outer 
mitochondrial membrane and cyt c release.  
The production of reactive oxygen species (ROS) can also facilitate apoptosis. 
Although ROS are by-products of normal mitochondrial function, high levels of ROS have 
been associated with p53-induced apoptosis, although the exact mechanism has not 
been elucidated yet (Fleury et al., 2002).  
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Autophagy 
Autophagy is a conserved catabolic mechanism consisting on the lysosomal 
degradation of intracellular components of cells. Through autophagy new metabolic 
substrates are provided to the cell, favouring its adaptation to stressful conditions and 
its survival [reviewed in (Yang and Klionsky, 2010)]. However, uncontrolled or 
excessive autophagy can lead to cell death [reviewed in (Mizushima et al., 2008)]. 
p53 can either activate or inhibit autophagy, depending on its subcellular localization 
[reviewed in (Ryan, 2011)]. Once in the nucleus, p53 directly activates the adenosine 
monophosphate activated protein kinase (AMPK) pathway in response to stress 
signals, resulting in the inhibition of the molecular target of rapamycin (mTOR) 
pathway and subsequent induction of autophagy (Feng et al., 2005). Several p53 
transcriptional targets encode pro-autophagic modulators, including AMPK, death 
associated protein kinase 1 (DAPK-1), damage-regulated autophagy modulator 1 
(DRAM1), pro-apoptotic Bcl-2 family proteins [Bad (Bcl-2 associated death 
promoter), Bax, Bnip3 (Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3), 
and PUMA], sestrin 2 (SESN2), and tuberous sclerosis protein 2 (TSC2) (Sui et al., 
2011). Besides p53, p73 can also activate DRAM, thus contributing to autophagy 
induction (Crighton et al., 2007). Interferon stimulated exonuclease gene 20 kDa-like 
1 (ISG20L1), which modulates genotoxic stress-induced autophagy, has been 
recently described as a p53 and p73 target (Eby et al., 2010).  
In the cytoplasm, p53 is able to inhibit autophagy through a 
transcription-independent mechanism. In contrast to its nuclear effects, in the 
cytoplasm, p53 inhibits AMPK and activates mTOR, although the molecular 
mechanism is still not fully understood (Tasdemir et al., 2008). 
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Fig. 5 – p53 distinctly regulates autophagy depending on its subcellular localization.  In the nucleus, p53 induces 
the expression of proteins that favour autophagy. In the cytoplasm, p53 inhibits autophagy through a 
transcription-independent mechanism [AMPK: adenosine monophosphate activated protein kinase; Bax: Bcl-2 associated 
X protein; DAPK: death associated protein kinase 1; DRAM1: damage-related autophagy modulator; ISG20L1: Interferon 
stimulated exonuclease gene 20 kDa-like 1; PUMA: p53 upregulated modulator of apoptosis; SESN2: sestrin 2; TSC2: 
tuberous sclerosis protein 2. Adapted from (Ryan, 2011)]. 
 
 
 
1.2. Endogenous modulators of p53 family proteins 
As referred above, the p53 family of proteins plays fundamental roles in the 
regulation of cellular proliferation and death. These cellular processes must be tightly 
regulated, since their disruption can lead to apoptosis related-diseases, resulting 
either from an excessive (degenerative disorders) or a deficient (neoplastic disorders) 
cell death (Reinhardt and Schumacher, 2012).  
The main endogenous modulators of p53 family proteins are MDM2 and 
MDMX (also called MDM4), which are oncoproteins found to be deregulated in many 
human tumours (Wade et al., 2013). These proteins share a high level of structural 
similarity and are thought to derive from the duplication of an ancestral gene 
(Momand et al., 2011). Both MDM2 and MDMX bind to a short α-helical stretch on 
the TAD of p53 through their N-terminal hydrophobic region, which is highly 
conserved (Böttger et al., 1999). Therefore, both MDM2 and MDMX are able to inhibit 
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the p53 activity by blocking the TAD (Kussie et al., 1996; Momand et al., 1992) (Fig. 
6). MDM2 and MDMX possess a zinc finger and an acidic region in their central 
portion, followed by a C-terminal RING finger domain, involved in homo- and 
heterodimerization. The two latter domains are essential for the E3 ubiquitin ligase 
activity in MDM2 (Lenos and Jochemsen, 2011). This RING finger domain mediates 
the interaction with an E2 ubiquitin conjugating enzyme, thereby bringing it into close 
proximity to its substrate proteins for ubiquitin conjugation [reviewed in (Glickman 
and Ciechanover, 2002)]. In fact, MDM2 is able to inhibit the p53 activity through 
ubiquitylation, either in the form of a homodimer or of a MDM2/MDMX heterodimer 
(Dolezelova et al., 2012; Uldrijan et al., 2007). In spite of the extensive sequence 
homology between its RING finger domain and that of MDM2, MDMX has no 
detectable E3 ubiquitin ligase activity in vivo (Kawai et al., 2003; Meulmeester et al., 
2003). However, Badciong and colleagues (2002) have reported that, in vitro, MDMX 
is capable of ubiquitylating p53, albeit with very low efficiency. 
When the levels of MDM2 are low, monoubiquitylation of p53 is favoured, 
leading to nuclear export and consequent inhibition of p53 transcriptional activity. 
Under these circumstances, monoubiquitylated p53 can localize to the mitochondria 
where it is deubiquitylated by the ubiquitin-specific protease-7 (USP7). Once 
deubiquitylated, p53 is able to induce apoptosis through a transcription-independent 
mechanism. Therefore, low levels of MDM2 are able to promote p53-mediated 
apoptosis (Marchenko et al., 2007). On the other hand, high levels of MDM2 favour 
polyubiquitylation of p53, which results in its proteasomal degradation (Fig. 6). This 
degradation mechanism is responsible for the maintenance of low levels of p53 in 
unstressed cells (Lee and Gu, 2010). Furthermore, under such unstressed 
conditions, it has been proposed that the MDM2/MDMX heterodimer may function as 
a more active ubiquitin ligase. In fact, heterodimer formation has been described to 
stabilize MDM2, and also to provide an extended motif for interaction with the E2 
ubiquitin conjugating enzyme (Linke et al., 2008).  
MDMX interaction with the TAD of p53 also prevents its interaction with p300, 
a protein involved in p53 activation through acetylation of certain lysine residues at 
the C-terminal. In this way, MDMX may indirectly stimulate MDM2-mediated p53 
inhibition, since these lysine residues are also targeted for ubiquitylation by MDM2 
(Lee and Gu, 2010).  
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Fig. 6 – Regulation of p53 by the negative modulators MDM2 and MDMX. Both MDM2 and MDMX bind to and inhibit 
p53 transcriptional activity. MDM2 is also able to promote p53 nuclear export and ubiquitylation, which results in 
proteasomal degradation (Ub: ubiquitin). 
 
 
 
Because of the structural similarities between p53 and its homologues, p63 and 
p73, it is plausible that MDM2 and MDMX might regulate these proteins in the same way 
as they regulate p53. In fact, it has been described that all three p53 family members 
encode a consensus sequence related to the MDM2 binding domain (Kallen et al., 2009; 
Kussie et al., 1996; Popowicz et al., 2007). Several groups attempted to identify and 
characterize these possible interactions, but results have often been controversial. 
Indeed, although it is widely accepted that both MDM2 and MDMX bind to and inhibit 
p73, albeit not inducing its degradation (Balint et al., 1999; Ongkeko et al., 1999; Wang 
et al., 2001; Zeng et al., 1999), data regarding a presumable interaction between these 
proteins and p63 is still contradictory. For example, it has been described that neither 
MDM2 nor MDMX are able to bind to p63 (Little and Jochemsen, 2001; Wang et al., 
2001). However, it has also been reported that p63 can interact with MDM2, but instead 
of the inhibitory effect observed with p53, this interaction results in an increase of p63 
transcriptional activity (Calabro et al., 2002). On the other hand, it has also been 
suggested that both MDM2 and MDMX are able to downregulate p63 transcriptional 
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activity, with equivalent efficiency, although not by inducing its degradation (Kadakia et 
al., 2001). Furthermore, according to this work, MDM2, but not MDMX, seemed to be 
able to induce the nuclear export of p63, thus inhibiting the p63-mediated apoptosis. 
More recently, Zdzalik and colleagues (2010) suggested that both p63 and p73 were 
able to interact with MDM2 and MDMX. This work predicted that p63 and p73 interact 
more strongly with MDMX than with MDM2, and that the binding affinities of MDM2 and 
MDMX for p53 and p73 were similar and stronger than those determined for p63. 
However, it is important to refer that for these determinations, the authors did not use 
the full-length proteins, but rather peptides containing the regions presumably involved 
in the interactions.  
 
Both MDM2 and MDMX are tightly regulated by several post-translational 
modifications that can either promote or inhibit their activities, and are also subjected to 
transcriptional regulation [reviewed in (Wade et al., 2010)]. Both MDM genes contain two 
promoters, P1 and P2, which give rise to identical transcripts. While P1 (located 
upstream of the first exon) controls the production of basal levels of these proteins, P2 
(located within exon 1) is highly regulated and is responsible for the inducible expression 
of MDM2 and MDMX (Barak et al., 1994; Manfredi, 2010; Zauberman et al., 1995). 
Indeed, MDM2 and MDMX expression can be induced by mitogens through activation of 
the P2 promoter (Gilkes et al., 2008; Ries et al., 2000). The P2 promoter of the MDM2 
gene has been found to contain a p53RE through which p53 is able to increase the 
MDM2 expression levels, thus establishing an auto-regulatory negative feedback loop, 
presumably as a way to prevent an exacerbated p53 activity (Wu et al., 1993). For a long 
time, it was thought that p53 was unable to induce the expression of MDMX. However, 
Wei and colleagues (2006) reported the existence of a p53RE within the first intron of 
the MDMX gene. Later, it was reported that p53 could, in fact, induce the transcription of 
MDMX (Li et al., 2010), through the P2 promoter (Phillips et al., 2010), thus establishing 
another negative regulatory feedback loop. 
Although some details about the modulation of p53 family proteins by MDM2 and 
MDMX are still not fully understood, it seems clear that the ratio between MDM2 and 
MDMX strongly determines the outcome of p53 stability. Moreover, it is also known that 
perturbations in this network have clear implications in tumourigenesis, representing 
promising opportunities for cancer therapy (Lenos and Jochemsen, 2011; Wade et al., 
2013). 
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1.3. Targeting p53 family proteins in cancer therapy 
Since p53 family proteins control many of the processes that ultimately determine 
cell proliferation, it is not surprising that these proteins play a fundamental role in cancer 
development and progression. In fact, TP53 is mutated in approximately 50% of all 
human tumours. Missense mutations within the DBD are the most frequently observed 
(Martinez, 2010). In tumours harbouring wt p53, p53 regulated signalling pathways are 
often inactivated due to overexpression of the p53 endogenous modulators MDM2 and 
MDMX (Brown et al., 2009). Furthermore, p53 is thought to become inactivated at some 
point of the progression of every tumour, since p53 inactivation has been described as 
a necessary condition for the maintenance of the tumour phenotype (Martins et al., 2006; 
Ventura et al., 2007; Xue et al., 2007). The relevance of p53 in tumourigenesis is also 
documented by the Li-Fraumeni syndrome, a rare disease resulting from germline 
mutations in the TP53 gene and characterized by an extremely high susceptibility for the 
development of tumours (Malkin, 1993). Similarly, TP53 deletion in mice increases 
susceptibility for cancer development, without causing any major developmental defect 
(Donehower et al., 1992).  
Besides its importance in tumour development, a functional p53 pathway is 
essential for an effective response to the anti-cancer drugs that trigger apoptosis by 
inducing DNA damage. (Chen et al., 2010).  
Due to their striking structural similarities with p53, it was initially hypothesized 
that p63 and p73 would function as classic tumour suppressors. However, the role of 
these proteins in tumourigenesis is still not fully understood. In spite of this, 
overexpression of specific isoforms of p63 and p73 has been described in some human 
tumours, and in some cases even related to an unfavourable prognosis [reviewed in 
(Deyoung and Ellisen, 2007)]. In p63+/- heterozygous mice, the susceptibility to tumour 
development is increased (Flores et al., 2005), while TP63 deletion is related to profound 
alterations of the skin and epithelial appendages, truncated limbs and craniofacial 
alterations, as well as premature death after birth (Mills et al., 1999). Although rare, p63 
mutations in humans are also related to developmental defects rather than cancer 
susceptibility [reviewed in (van Bokhoven and Brunner, 2002)]. However, p63 
overexpression, particularly of ΔNp63α, has been demonstrated in up to 80% of primary 
head and neck squamous cell carcinomas (Sniezek et al., 2004; Weber et al., 2002). 
Furthermore, loss of p63 expression is observed in a subset of invasive bladder 
carcinomas, and it appears to be related to invasion, metastasis, and thus, poor 
prognosis (Park et al., 2000; Urist et al., 2002).  
In mice, deletion of TP73 results in premature death as a result of inflammation 
and recurring infections. Additionally, these animals suffer from various neurological 
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abnormalities (Yang et al., 2000). Concerning to tumour susceptibility, TAp73-/- mice are 
tumour prone, displaying genomic instability, while ΔNp73 knockouts show increased 
sensitivity to DNA-damaging agents (Tomasini et al., 2008; Wilhelm et al., 2010). Indeed, 
it has been described that, in humans, the DNA damage induced by specific 
chemotherapeutic agents results in TAp73 activation, which appears to be fundamental 
for triggering apoptosis (Gong et al., 1999; Yuan et al., 1999). Overexpression of 
N-terminally truncated isoforms of p73 has been described in many types of human 
cancer, and appears to be related to the formation of metastases, poor response to 
chemotherapeutic drugs, and unfavourable patient prognosis (Dominguez et al., 2006; 
Wager et al., 2006). Increased expression of TA isoforms of p73 has also been described 
in some tumours, which contradicts its role as a tumour suppressor. It is thought that, 
under specific circumstances, TAp73 isoforms may act as a tumour promoters, rather 
than a tumour suppressors, although the molecular mechanisms mediating these 
functions are still not elucidated (Vikhanskaya et al., 2007). 
Hence, the contribution of p53 family proteins to cancer development appears to 
result from an interplay between different isoforms of its members. Additionally, whether 
p63 and p73 promote or inhibit tumourigenesis appears to depend on the predominant 
isoforms expressed in a given context. The understanding of how each protein functions 
at a molecular level is therefore of extreme importance for their potential targeting in 
anti-cancer therapy [reviewed in (Deyoung and Ellisen, 2007)].  
Based on that exposed above, activation of p53 in tumour cells has been 
considered a promising anti-cancer therapeutic strategy  
One strategy to achieve p53 reactivation in tumours is gene therapy. In fact, 
adenovirus-based p53 therapies, aiming the restoration of the TP53 gene, have reached 
phase III clinical trials, demonstrating anti-tumour activity, without significant adverse 
effects. These results were extremely encouraging for the development of p53-target 
based therapies (Huang et al., 2009). 
In addtion, the direct pharmacological activation of p53 is still of particular interest 
in the treatment of tumours expressing mutant variants of this protein. However, based 
on the conventional drug development process, p53 is not an ideal therapeutic target, 
since it is neither an enzyme nor a receptor. Furthermore, the forms of inactivated p53 
in human tumours are extremely diverse, with more than 2000 types of mutations 
currently described. Despite the difficulties associated with the development of drugs 
targeting p53, recent technological advances, in association with the knowledge 
obtained over the past 30 years about p53 family proteins, make this a recent promising 
strategy for anti-cancer therapy [reviewed in (Chen et al., 2010)]. In fact, some promising  
small molecules able to reactivate mutant p53 have been developed, such as PRIMA-1 
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(Bykov et al., 2002) and CP-31398 (Rippin et al., 2002), the latter having been also 
described as an activator of wt p53 (Wang et al., 2003). 
The pharmacological reactivation of p53, in tumours harbouring a wt p53, may 
also be achieved through inhibition of its interaction with either MDM2 or MDMX. In fact, 
recent advances in the development of  small molecule inhibitors of protein-protein 
interactions have opened the way for a new class of drug targets. Moreover, the 
successful development of p53-MDM2 interaction inhibitors confirms the feasibility of this 
therapeutic approach (Vassilev, 2004; Vassilev et al., 2004). So far, inhibitors of the 
p53-MDM2 interaction have adequate safety profiles and are able to selectively induce 
cancer cell death (Shangary and Wang, 2009). Nutlin-3a is a  small molecule that fits the 
p53-binding pocket in MDM2, thus inhibiting its interaction with p53, which leads to p53 
stabilization and activation. This compound triggers cell cycle arrest and apoptosis, and 
was able to reduce tumour growth in a nude mice xenograft model (Vassilev et al., 2004). 
Currently, there are two ongoing phase I clinical trials, where RG7112 (a derivative of 
nutlin-3a, also named RO5045337) is being tested in patients with myelogenous 
leukemia (ClinicalTrials.gov identifiers: NCT01635296 and NCT01677780; last access 
12th August 2013). RITA is another example of a p53-MDM2 interaction inhibitor, but 
unlike nutlin-3a, it binds to p53 instead of MDM2. RITA inhibits the p53 interaction with 
MDM2 both in vitro and in vivo, and induces apoptosis in various human cells expressing 
wt p53 (Issaeva et al., 2004). Regarding the p53 interaction with MDMX, SJ-172550, 
which binds reversibly to MDMX, was the first described inhibitor. This compound was 
shown to effectively reduce the growth of retinoblastoma cells that overexpress MDMX 
(Reed et al., 2010).  
Activation of pro-apoptotic isoforms of p63 and p73 may also be a promising 
strategy for anti-cancer therapy. However, further studies are still required in order to 
fully understand how these proteins control cellular proliferation and death. A  small 
molecule named RETRA has been shown to increase the p73 expression in cells with 
mutant p53, leading to a p53-like tumour suppression; nevertheless, its molecular 
mechanism is still unclear (Kravchenko et al., 2008). 
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1.4. Yeast model in the study of p53 family proteins  
The p53 family proteins participate in extremely complex signal transduction 
pathways, which are still not fully elucidated in mammalian cells, in part due to the 
coexistence of many isoforms of each protein. One strategy to overcome this issue 
is the use of simpler model organisms, such as the yeast Saccharomyces cerevisiae, 
in which the role of each protein isoform can be analysed individually without 
interference from other proteins.  
There are several advantages in the use of this eukaryotic organism as a 
model to study disease-related proteins, including its ease of manipulation, short 
generation time and compliance to genetic manipulation. In fact, S. cerevisiae has 
greatly contributed to the elucidation of basic cellular processes related to cell cycle, 
cell death, and organelle biosynthesis, among many others. Moreover, the 
heterologous expression of human proteins in yeast (commonly referred to as 
“humanized yeast”) has provided important clues about the pathways in which they 
are involved, due to the conservation of human cell signalling networks and protein 
interactions in this organism. Yeast has in fact highly contributed to the elucidation of 
the molecular mechanisms underlying the pathobiology of several human diseases 
[reviewed in (Pereira et al., 2012a; Pereira et al., 2012b)].  
No orthologues of p53 family proteins or of their endogenous modulators, 
MDM2 and MDMX, have been identified in S. cerevisiae (Smardova et al., 2005; 
Yousef et al., 2008). Therefore, through heterologous expression, it has been 
possible to study the activity of individual human proteins of the p53 family, in a 
simplified cellular background, without the interference of other members of this 
family of proteins, which often display similar or even overlapping functions. 
Several yeast-cell based assays have been developed in recent years, for 
functional, molecular and pharmacological studies of p53 family proteins. One of the 
first techniques to be developed was the yeast FASAY assay, which consists of a 
functional analysis of the separated alleles of TP53 in yeast in order to evaluate the 
p53 activity in cancer cells, as described (Ishioka et al., 1993). Using an improved 
version of the FASAY assay, developed by Flaman et al. (1995), it was verified that 
some TP53 mutations led to the partial loss of the p53 transactivation function 
(Kovvali et al., 2001). The more recently developed dual-luciferase functional assay 
is another type of yeast-based transactivation assay (Fig. 7) (Andreotti et al., 2011). 
This transactivation assay uses a luciferase reporter gene containing a p53RE placed 
upstream of a minimal promoter (pCYC1), which is integrated as a single copy at a 
chromosomal locus of yeast cells expressing p53. In this way, when wt p53 is 
activated, it will bind to the p53RE, inducing the transcription of the luciferase reporter 
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gene and the synthesis of luciferase. Therefore, the p53 transcriptional activity may 
then be assessed through quantification of the light emitted, which is directly 
proportional to the luciferase oxidative activity. Recently, this dual-luciferase 
transactivation assay was adapted to the high throughput screening (HTS) of small 
molecules and co-factors [e.g. MDM2 and 53BP1 (p53-binding protein 1)] modulators 
of p53 (Andreotti et al., 2011). In spite of all the advantages of this yeast-based assay, 
it is an artificial (since it relies on the insertion of a human reporter gene containing a 
p53RE in yeast cells) and expensive cell system for HTS.  
 
 
 
 
Fig. 7 – Yeast-based p53 luciferase transactivation assay using cells (A) expressing human wt p53 or (B) 
co-expressing human wt p53 and a cofactor. This assay utilizes the luciferase reporter gene. While a common minimal 
promoter (pCYC1) controls low-level constitutive expression of the reporter gene, p53-dependent expression of the 
luciferase is achieved through a specific p53RE placed upstream of the minimal promoter. The p53 transcriptional activity 
is evaluated by quantification of the luciferase activity, which is directly proportional to the light units measured in a plate 
reader [adapted from (Pereira et al., 2012b)]. 
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Studies with such model systems have demonstrated that human wt p53 also 
acts as a sequence-dependent transcription factor in yeast (Coutinho et al., 2011; 
Fields and Jang, 1990; Scharer and Iggo, 1992). Also, they allowed to verify that the 
heterologous expression of this protein in yeast causes a mild growth inhibition, 
associated with increased apoptosis (Hadj Amor et al., 2008) or, depending on the 
S. cerevisiae strain used, with S-phase cell cycle arrest (Coutinho et al., 2009; Nigro 
et al., 1992).  
Yeast has been also used to study the regulation of p53 by protein kinase C 
(PKC) isoforms. Particularly, in a recent work from our group, the effect of different 
PKC isoforms on wt p53 activity was studied (Coutinho et al., 2009). In this work, it 
was shown that, in the absence of a stress stimulus, PKCα reduced the p53 toxic 
effects in yeast (growth inhibition and S-phase cell cycle arrest), while the novel 
PKCδ and ε isoforms enhanced the p53 activity through p53 phosphorylation at 
Ser376-378 residues. For PKCζ, no effects on p53 activity were observed. These 
conclusions, obtained for PKCδ and ε, were further confirmed by a subsequent study 
performed by our group in yeast cells exposed to the apoptotic stimulus, H2O2 
(Coutinho et al., 2011). In this study, it was shown that while PKCα and ζ did not 
affect the p53 activity, PKCδ and ε stimulate the p53 transcription-dependent 
and -independent apoptotic pathway through phosphorylation at Ser376-378. With 
this study, the conservation in yeast of a p53 transcription-independent mechanism, 
characterized by mitochondrial translocation of p53, was revealed for the first time. 
Additionally, further insights about the mitochondrial p53 translocation were provided. 
Particularly, PKCδ and ε were identified for the first time as possible inducers of the 
p53 translocation to the mitochondria (Fig. 8). 
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Fig. 8 – Human wt p53 is distinctly regulated by PKC isoforms. The expression of wt p53 in S. cerevisiae caused cell 
growth inhibition associated with S-phase cell cycle arrest. (A) In the absence of an apoptotic stimulus: cPKCα negatively 
regulated the p53 growth-inhibitory effect, leading to an increase in the percentage of cells arrested in G2/M phase; nPKCδ 
and ε stimulated the p53-induced growth inhibition, which was accompanied by a marked increase on p53 phosphorylation 
at Ser376-378 residues and in the percentage of cells arrested in S-phase. aPKCζ did not interfere with p53 effect. (B) In 
the presence of an apoptotic stimulus: a differential regulation of p53-mediated apoptosis was obtained by PKCα, δ, ε and 
ζ. Contrary to PKCα and ζ, which did not interfere with p53 activity, PKCδ/ ε markedly increase the p53 activity, leading 
to an increase of a set of mitochondrial alterations, through p53 phosphorylation at Ser376-378. In addition, PKC δ and ε 
stimulated mitochondrial p53 translocation (*), an effect reverted by pifithrin-μ (PFT-μ; a selective inhibitor of mitochondrial 
p53 translocation). 
 
 
 
Furthermore, it was shown MDM2 is also able to interact with endogenous 
yeast pathways in order to promote p53 ubiquitylation and subsequent degradation 
(Di Ventura et al., 2008). In fact, as in mammalian cells, when co-expressed with wt 
p53, MDM2 markedly reduced the p53 activity in yeast, an effect abolished by the 
inhibitor of the p53-MDM2 interaction, nutlin-3a (Leao et al., 2013). Using this yeast 
phenotypic assay, a new inhibitor of the p53-MDM2 interaction with a xanthone 
scaffold (LEM1) was discovered, and its molecular mechanism was further confirmed 
in human tumour cells (Leao et al., 2013).  
Accumulating evidence have been, therefore, provided showing the suitability 
of the yeast model system for the study of molecular mechanisms of p53 family 
proteins, and for the pharmacological screening of modulators of p53 family proteins 
as potential anti-cancer drugs.  
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1.5. Aims of research 
With the present project, it was intended:  
 
a) To search for new inhibitors of the p53-MDM2 interaction, using a previously 
developed yeast-based p53-MDM2 screening assay; 
b) To validate, in human tumour cell lines, the molecular mechanism of action of 
potential activators of p53 identified in a previous work using the yeast-based 
p53-MDM2 screening assay; 
c) To develop a new yeast-based p53-MDMX screening assay for the search of 
inhibitors of the p53-MDMX interaction; 
d) To identify an endogenous p53 target gene in order to develop a simplified and 
cost-effective yeast p53 transcription assay, as an alternative to the artificial 
yeast reporter strains, for the analysis of the impact of mutants, cofactors and  
small molecules on p53 transcriptional activity; 
e) To study the role of p63, ΔNp63 and p73 in cell proliferation and death using 
the yeast cell system.  
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2. Materials and Methods 
2.1. Compounds 
Compounds used as controls included: nutlin-3a (Alexis Biomedicals) and 
SJ-172550 (Sigma-Aldrich), known inhibitors of the interaction of p53 with MDM2 and 
MDMX, respectively (Reed et al., 2010; Vassilev et al., 2004); pifthrin-α (PFT-α; 
Sigma-Aldrich), a selective inhibitor of p53 transcriptional activity (Gudkov and 
Komarova, 2005); and doxorubicin (Sigma-Aldrich), a conventional chemotherapeutic 
agent. Rapamycin (Sigma-Aldrich), an inhibitor of mTOR, was used for autophagy 
induction in yeast (Noda and Ohsumi, 1998).  
α-mangostin (αMG) was extracted from the mangosteen fruit of Garcinia 
mangostana L. (Clusiaceae) (Fig. 9) by Professor José Pedraza-Chaverri (from Facultad 
de Química, Universidad Nacional Autónoma de México), as previously described 
(Marquez-Valadez et al., 2009). Gambogic acid (GA; Fig. 9) and 3,7-dihydroxyflavone 
(3,7DHF; Fig. 12) were purchased from Sigma-Aldrich. The chalcones 4-benzyloxy-2’,4’-
dihydroxychalcone (C1), 2’,4’-dihydroxy-3,4,5-trimethoxy-3’-propylchalcone (C2), 
2’,4’-dihydroxy-4-methoxy-3’-propylchalcone (C3), 3,4,4’,5,6’-pentamethoxy-2’-
prenyloxychalcone (C4), 3,4,5-trimethoxy-4’,6’-bis(methoxymethoxy)-3’-prenylchalcone 
(C5) (Fig. 12), were synthesized by Professor Honorina Cidade (CEQUIMED-UP), as 
previously described (Neves et al., 2012a; Neves et al., 2012b). 
All the referred compounds were dissolved in dimethyl sulfoxide (DMSO; 
Sigma-Aldrich). 
 
 
2.2. Plasmids 
The yeast expression vectors used in the yeast assays were: pGADT7-(LEU2) 
encoding human MDM2 under the control of the ADH1 constitutive promoter (kindly 
provided by Dr. Xue-Min Zhang from National Center of Biomedical Analysis, China); 
pGADT7-(LEU2) encoding human MDMX under the control of the ADH1 constitutive 
promoter (kindly provided by Dr. Martin Scheffner from University of Konstanz, 
Germany); pLS89-(TRP1) encoding human wt p53 or human mutant p53 V122A under 
the control of the GAL1-10 inducible promoter (kindly provided by Dr. Richard Iggo from 
the Swiss Institute for Experimental Cancer Research, Switzerland); pLS76-(LEU2) 
encoding human mutant p53 R280K or R273H, under the control of the constitutive 
ADH1 promoter; pRS314-(TRP1) encoding human TAp63α or ΔNp63α under the control 
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of the GAL1-10 inducible promoter (kindly provided by Dr. Gilberto Fronza from Istituto 
Nazionale per la Ricerca sul Cancro, Italy); pRS314-(TRP1) encoding human TAp73α 
under the control of the GAL1-10 inducible promoter (kindly provided by Dr. Alberto Inga 
from Centre for Integrative Biology, Italy); the yeast integrative ABP140-3xGFP-(LEU2) 
plasmid (kindly provided by Dr. Isabelle Sagot from Institut de Biochimie et Génétique 
Cellulaires, France) was used in actin depolarization experiments. 
 
 
2.3. Yeast strains, transformation, and growth conditions 
The yeast Saccharomyces cerevisiae strains used were: CG379 (α ade5 his7-2 
leu2-112 trp1-289α ura3-52 [Kil-O], Yeast Genetic Stock Center, University of California, 
USA), W303 (α ura3-1 leu2-3, 112 his3-11, 15 trp1-1 ade2-1 can1-100; Yeast Genetic 
Stock Center, University of California, USA), W303 atg1Δ::KanMX4 (Yorimitsu et al., 
2007; kindly provided by Dr. Daniel Klionsky from University of Michigan, Life Sciences 
Institute, USA), and W303 atg5Δ::KanMX4 (Kissova, et al. 2004; kindly provided by Dr. 
Stefan Manon from CNRS, UMR5095, Université de Bordeaux, France). Yeast cells 
were transformed using the standard lithium acetate method (Ito et al., 1983) and were 
routinely grown in minimal selective medium with 2% (w/w) glucose, 0.7 % (w/w) yeast 
nitrogen base without amino acids (Difco), and all the amino acids required for yeast 
growth (50 μg/mL) except leucine or tryptophan (for single expression systems), or 
except leucine and tryptophan (for co-expression systems). For expression of human 
proteins, cells were diluted to 0.05 OD600 in selective induction medium, in which glucose 
was replaced by 2% (w/w) galactose and 2% (w/w) raffinose. Yeast cells were then 
incubated at 30 °C, under continuous orbital shaking (200 rpm) for approximately 30 h 
(for single expression systems) or 42 h (for co-expression systems), corresponding to 
the time required by control yeast (transformed with the empty vectors) to achieve 0.5 
OD600. Yeast cell growth was analysed by counting the number of colony-forming units 
(CFU) after 2 days incubation at 30 °C on Sabouraud Dextrose Agar plates (Liofilchem). 
 
 
2.4. Western blot analysis 
To analyse protein expression in yeast, samples were lysed with CellyticTM Y Cell 
Lysis Reagent (Sigma-Aldrich) in the presence of EDTA-free protease inhibitor cocktail 
(Sigma-Aldrich). Following whole protein quantification, using the Bio-Rad Protein Assay 
(Bio-Rad) according to manufacturer’s instructions, proteins (40 μg) were 
electrophoresed on 10% SDS-PAGE and transferred to an Amersham nitrocellulose 
membrane (GE Healthcare). Membranes were blocked with 5% milk and probed with the 
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following antibodies: mouse monoclonal anti-p53 (DO-1; Santa Cruz Biotechnology) for 
the detection of wt and mutant forms of p53; mouse monoclonal anti-p63 (4A4; Santa 
Cruz Biotechnology) for TAp63α and ΔNp63α detection; rabbit polyclonal anti-p73 
(AB7284; Milipore) for TAp73α detection; rabbit polyclonal anti-MDMX (A300; Bethyl 
Laboratories); rabbit polyclonal anti-Atg8p (y-117; Santa Cruz Biotechnology); rabbit 
polyclonal anti-actin (C11; Santa Cruz Biotechnology). Membranes were, then, probed 
with either anti-mouse or anti-rabbit horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Santa Cruz Biotechnology). For loading control, membranes were 
stripped and reprobed with a mouse anti-yeast phosphoglycerate kinase (Pgk1p) 
antibody (Molecular Probes). The signal was detected by chemiluminescence with the 
ECL Amersham kit (GE Healthcare). Band intensities were quantified using the Bio-Profil 
Bio-1D++ software (Vilber-Lourmat). 
 
 
2.5. Effect of compounds on yeast cell growth 
To evaluate the effect of α-mangostin and gambogic acid, on yeast cell growth, 
yeast cells co-expressing human wt p53 and MDM2 [obtained in previous work (Leao 
et al., 2013)] or p53 R280K alone, were incubated in selective induction medium with 
10 μM nutlin-3a, 1 – 100 μM α-mangostin (αMG) or gambogic acid (GA), or with 0.1% 
DMSO only, for approximately 42 h (for analysis of the effect on the p53-MDM2 
interaction) or 30 h (for analysis of the effect on p53 R280K), at 30 °C, under 
continuous shaking. As a positive control, yeast cells were incubated, in the same 
conditions, with nutlin-3a. Yeast cell growth was analysed by CFU counts, as 
described above. 
 
 
2.6. Yeast cell cycle analysis 
Yeast cell cycle progression was examined by flow cytometric analysis of DNA 
content using Sytox Green Nucleic Acid stain (Invitrogen), as previously described 
(Fortuna et al., 2001). Briefly, 1 × 107 cells were fixed overnight in 70% (v/v) ethanol, at 
4 °C. Cells were then washed with sodium citrate buffer and incubated for 3 h, first with 
250 μg/mL RNase A (Sigma-Aldrich), then with 1 mg/mL Proteinase K (Sigma-Aldrich), 
and finally stained with 10 µM Sytox Green Nucleic Acid stain (Invitrogen) for 
approximately 12 h. For the flow cytometric analysis the FACSCalibur flow cytometer 
(BD Biosciences) and the CellQuest software (BD Biosciences) were used. Yeast cell 
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cycle phases were identified and quantified using ModFit LT software (Verity Software 
House Inc.). 
 
 
2.7. Cell death assays 
To assess plasma membrane integrity, transformed S. cerevisiae CG379 cells 
were incubated with 5 μg/mL PI (Molecular Probes) for 10 minutes at room temperature, 
and the fluorescence analysed by flow cytometry using the FACSCalibur flow cytometer 
(BD Biosciences) and the CellQuest software (BD Biosciences). To monitor DNA 
fragmentation in yeast, the TUNEL assay was carried out using the In Situ Cell Death 
Detection Kit, Fluorescein (Roche Applied Science) as previously described (Saraiva et 
al., 2006). Samples were observed under a fluorescence microscope (Eclipse E400 
fluorescence microscope, Nikon) under appropriate filter setting.  
For the apoptotic cell death analysis, transformed S. cerevisiae CG379 cells, 
previously grown in minimal selective medium to 0.3 OD600, were treated with 1.5 and 
5 mM H2O2 for 1 h at 30 °C under continuous shaking. Cell death was assessed by 
counting the number of CFU/mL after 1 day incubation at 30 °C on Sabouraud Dextrose 
Agar plates. For each transformed yeast cells, the percentage of dead cells was 
estimated considering 100% survival (0% death) as the number of CFU obtained with 
cells incubated in the same conditions without H2O2. 
 
 
2.8. Autophagy analysis 
For the autophagy analysis, S. cerevisiae wt W303, W303 atg1Δ, and W303 
atg5Δ cells expressing a p53 family member and control yeast were grown in induction 
selective medium for 30 h, and cell growth was analysed by counting the number of CFU. 
Additionally, transformed S. cerevisiae CG379 cells expressing a p53 family member 
and control yeast were grown in induction selective medium to 0.35 OD600 before 
treatment with 0.2 µg/mL rapamycin for 4 h at 30 ºC. The viability of rapamycin-treated 
yeast cells was assessed by CFU counts, considering the number of CFU obtained with 
yeast cells incubated with DMSO only as 100%. 
 
 
2.9. Analysis of actin depolarization 
Yeast actin organization was analysed using yeast expressing wt p53 and control 
yeast (transformed with the empty vector) co-transformed with the yeast integrative 
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ABP140-3xGFP-(LEU2) plasmid. Fluorescence microscopic examinations were 
performed with an inverted laser-scanning confocal microscope (Olympus FV 
1000/IX81) equipped with a 60× magnification objective lens (Olympus PlanApo 
60x/1.42 NA, oil). GFP was excited with the 488 nm Multi-line Argon laser. The emitted 
fluorescence was detected at 505-520 nm using the scanner of the confocal microscope. 
The area of labelling was analysed using the FluoView Advanced Software (ASW, v.1.4; 
Olympus). 
 
 
2.10. Effect of compounds on the in vitro cell growth of human tumour 
cell lines 
The effect of 3,7-dihydroxyflavone (3,7DHF) and chalcones C1 – C5 was 
evaluated on a human colon carcinoma cell line with (HCT116 p53+/+) and without 
(HCT116 p53-/-) p53 using the protein-binding dye sulforhodamine B to assess cell 
growth (Vichai and Kirtikara, 2006). Briefly, cells were plated in 96-well plates at a density 
of 5 × 103 cells/well, in RPMI-1640 medium with ultragltamine I (Lonza) supplemented 
with 5% fetal bovine serum (Gibco), and allowed to adhere overnight in a humidified 
incubator at 37 °C with 5% CO2 in air. Cells were further incubated for 48 hours with five 
serial dilutions of each compound (150, 50, 16.67, 5.56 and 1.85 μM). Doxorubicin and 
nutlin-3a were used as a positive controls. The effect of the vehicle solvent on the growth 
of these cell lines was also evaluated, by exposing untreated control cells to the 
maximum concentration of DMSO used in each assay (0.075%). Following incubation, 
cells were fixed in situ with ice cold 10% trichloroacetic acid, washed, and stained with 
sulforhodamine B. Unbound stain was washed with 1% acetic acid and the bound stain 
was solubilized in 10mM Tris Base. Finally, optical density was measured at 510 nm 
using a microplate reader (Synergy HT; Biotek). The GI50 values (concentration resulting 
in 50% inhibition of cell growth) were determined for each compound from the plotted 
results.  
 
 
2.11. Statistical analysis 
Data were analysed statistically using the SigmaStat 3.5 software. Differences 
between means were tested for significance using the unpaired Student’s t-test 
(P < 0.05). 
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3. Results 
3.1. Searching for  small molecule activators of p53 activity 
3.1.1.  Inhibitors of the p53-MDM2 interaction 
 
In a previous study, our group identified an inhibitor of the p53-MDM2 interaction with 
a xanthone scaffold (Leao et al., 2013). Based on this, it was hypothesized that α-mangostin 
(αMG) and gambogic acid (GA) (Fig. 9), two xanthones with well-known potent anti-tumour 
properties, could also modulate the p53-MDM2 interaction. 
 
 
 
 
Fig. 9 – Chemical structures of α-mangostin (αMG) and gambogic acid (GA). 
 
 
 
To test this hypothesis, a yeast model previously developed by our group (Leao et 
al., 2013) was used. In this yeast phenotypic assay, the expression of human wt p53 alone 
causes growth inhibition associated with S-phase cell cycle arrest (Fig. 10A, C), as 
previously described (Coutinho et al., 2009). Furthermore, although the expression of human 
MDM2 alone did not interfere with cell growth and cell cycle progression, its co-expression 
with wt p53 significantly reduced the p53-dependent growth inhibition and cell cycle arrest 
(Fig. 10A, C). In this assay, nutlin-3a, a known inhibitor of the p53-MDM2 interaction 
(Vassilev et al., 2004), was used as a positive control. As previously described (Leao et al., 
2013) nutlin-3a was able to abolish the inhibitory effect of MDM2 on p53-induced growth 
inhibition and cell cycle arrest (Fig. 10A, C), thus supporting the effectiveness of this yeast 
model to search for inhibitors of the p53-MDM2 interaction.  
Therefore, using this assay, the effects of 1 – 100 μM of αMG and GA on the 
p53-MDM2 interaction were evaluated. From the concentration-response curves obtained 
(Fig. 10B), the concentration of 10 μM was selected for both xanthones as the lowest 
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concentration at which a significant reversion of the MDM2 effect was obtained, while not 
affecting the growth of control yeast (transformed with the empty vectors). At a concentration 
of 10 μM, similarly to nutlin-3a, both xanthones were able to re-establish the p53-induced 
growth inhibition and S-phase cell cycle arrest in yeast cells co-expressing p53 and MDM2, 
while having no effect on control yeast, or on yeast expressing p53 or MDM2 alone (Fig. 
10A, C). 
 
 
 
  
 
Fig. 10 – α-Mangostin (αMG) and gambogic acid (GA) revert the inhibitory effect of MDM2 on p53-induced growth 
inhibition and S-phase cell cycle arrest in yeast. (A) Effects of 10 µM nutlin-3a and 10 µM αMG and GA on the growth 
of control yeast, yeast expressing only p53 and yeast co-expressing p53 and MDM2. Results were estimated considering 
the number of CFU obtained with control yeast (empty vectors) as 100% growth. The growth of yeast expressing MDM2 
alone treated with compounds was approximately 100%, therefore it is represented by the control yeast. Data are 
represented as mean ± SEM of five independent experiments; values obtained with yeast co-expressing p53 and MDM2 
treated with the compound were significantly different from DMSO only (*P < 0.05). (B) Effects of 1-100 µM αMG and GA 
on the reduction of p53-induced growth inhibition by MDM2 in yeast co-expressing p53 and MDM2. Data are represented 
as mean ± SEM of four independent experiments; values significantly different from DMSO only (*P < 0.05). (C) Effects 
of 10 µM nutlin-3a and 10 µM αMG and GA on the reversion of p53-induced S-phase cell cycle arrest by MDM2; data are 
represented as mean ± SEM of two independent experiments; values significantly different from DMSO only (*P < 0.05).  
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In previous work, it was shown that αMG was cytotoxic against a human 
adenocarcinoma cell line (MDA-MB-231) which harbours the mutant variant of p53, 
R280K (Shibata et al., 2011). Based on this, the activity of both αMG and GA on 
mutant p53 R280K was also evaluated using this yeast-based growth assay. In this 
assay, contrary to wt p53, the expression of p53 R280K mutant (confirmed by 
Western blot analysis; Fig. 11A) had no effect on yeast cell growth, when compared 
to control yeast (Fig. 11B). As such, activators of this mutant variant of p53 would 
re-establish the wt p53-dependent growth inhibition. The results obtained showed 
that neither αMG nor GA were able to affect the growth of yeast cells expressing p53 
R280K (Fig. 11B).  
 
 
 
 
Fig. 11 – α-Mangostin (αMG) and gambogic acid (GA) do not interfere with the activity of mutant p53. (A) 
Expression of human mutant p53 (R280K) in yeast was confirmed by Western blot analysis. Pgk1p was used as loading 
control. Immunoblots are representative of two independent experiments. (B) Effects of 10 µM αMG and GA on the growth 
of yeast expressing mutant p53. Results are plotted setting as 100% growth the number of CFU obtained with control 
yeast (empty vector). Data are represented as mean ± SEM of four independent experiments; values significantly different 
from control yeast (*P < 0.05). 
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3.1.2.  Activators of p53 
 
In a previous work performed by our group, in which a library of flavonoids 
(from CEQUIMED-UP) was screened, using the yeast-based p53-MDM2 assay (Leao 
et al., 2013), six compounds emerged as potential activators of wt p53: 3,7DHF and 
chalcones C1 – C5 (Fig. 12). 
 
 
 
 
Fig. 12 – Chemical structures of the six flavonoids tested. 3,7-dihydroxyflavone (3,7DHF), 4-benzyloxy-2’,4’-
dihydroxychalcone (C1), 2’,4’-dihydroxy-3,4,5-trimethoxy-3’-propylchalcone (C2), 2’,4’-dihydroxy-4-methoxy-3’-
propylchalcone (C3), 3,4,4’,5,6’-pentamethoxy-2’-prenyloxychalcone (C4), 3,4,5-trimethoxy-4’,6’-bis(methoxymethoxy)-
3’-prenylchalcone (C5). 
 
 
 
In order to confirm if the mechanism of action of these compounds involved 
p53 activation, their effects on the growth of human colon carcinoma cell lines with 
(HCT116 p53+/+) and without (HCT116 p53-/-) wt p53 were assessed by the 
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sulforhodamine B assay. A concentration-dependent response curve was obtained 
for each compound, in both cell lines, and the concentration that caused 50% of cell 
growth inhibition (GI50) was determined as previously described (Monks et al., 1991) 
(Table 1). In general, all the tested flavonoids exhibited potent anti-proliferative 
effects against the two human colon carcinoma cell lines studied. In spite of this, 
contrary to nutlin-3a and doxorubicin [positive controls, both of which have been 
described to act via p53 (Fritsche et al., 1993; Vassilev et al., 2004)], the GI50 values 
determined for the six flavonoids were similar for both cell lines, suggesting they were 
not dependent on the p53 status. This indicated a non p53-dependent cell growth 
inhibitory effect for all the tested flavonoids.  
 
 
 
Table 1 – GI50 values obtained for the tested flavonoids in colon carcinoma cell lines with or without wt p53. 
 
 GI50 (μM) 
Compounds HCT116 p53+/+ HCT116 p53-/- 
3,7DHF 36.3 ± 1.4 39.7 ± 1.9 
C1 9.57 ± 0.78 8.63 ± 0.56 
C2 4.63 ± 0.59 3.13 ± 0.26 
C3 24.3 ± 4.8 15.7 ± 2.4 
C4 4.00 ± 0.36 3.73 ± 0.27 
C5 2.50 ± 0.19 2.40 ± 0.33 
Doxorubicin 0.136 ± 0.029 0.450 ± 0.042* 
Nutlin-3a 3.67 ± 0.34 24.0 ± 0.7* 
Nutlin-3a and doxorubicin were used as positive controls. Data are represented as mean ± 
SEM of three independent experiments performed in duplicate. Values significantly different 
from HCT116 p53+/+ (*P < 0.05) 
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3.2. Development of a yeast-based assay to search for inhibitors of 
the p53-MDMX interaction 
 
In order to study the regulatory effect of MDMX on p53 activity in yeast, the 
human MDMX was expressed in these cells either alone or combined with human wt 
p53 (Fig. 13A). Similarly to MDM2 (Leao et al., 2013), although the single expression 
of MDMX in yeast did not interfere with the cell growth and cell  cycle progression, its 
co-expression with p53 significantly reduced the p53-induced growth inhibition (Fig. 
13B, DMSO) and S-phase cell cycle arrest (from 18.0 ± 1.2%, obtained with cells 
expressing only p53, to 5.9 ± 1.9%, n = 2, P < 0.05; Fig. 13C, DMSO).  
The efficiency of this assay for the screening of inhibitors of the p53-MDMX 
interaction, was assessed by testing the known inhibitor of the p53-MDMX interaction, 
SJ-172550 (Reed et al., 2010). In this assay, inhibitors of the p53-MDMX interaction 
would abolish or significantly reduce the negative effect of MDMX on p53 activity. As 
expected, 20 µM SJ-172550 significantly reduced the negative effect of MDMX on 
p53-induced growth inhibition (Fig. 13B) and S-phase cell cycle arrest (from 5.9 ± 
1.9%, obtained with DMSO only, to 15.8 ± 1.5%, n = 2, P < 0.05; Fig. 13C), without 
interfering with the activity of p53 and MDMX when expressed alone (Fig. 13B, C). In 
fact, after 42 h treatment with 20 µM SJ-172550, approximately 83% of the 
p53-induced growth inhibition and S-phase cell cycle arrest were re-established. 
Higher concentrations of SJ-172550 did not improve the reversion of the MDMX effect 
on p53-induced growth inhibition (Fig. 13D). Furthermore, from 50 μM SJ-172550, a 
cytotoxic effect on control yeast (empty vectors) was observed (Fig. 13E). On the 
other hand, SJ-172550 concentrations lower than 20 μM did not significantly reduce 
the negative effect of MDMX on p53 induced growth inhibition (Fig. 13D). Additionally, 
for 0.1 – 20 μM, SJ-172550 had no effect on the growth of yeast expressing p53 alone 
(Fig. 13E). 
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Fig. 13 – MDMX inhibits the impact of p53 on the growth of yeast, an effect abolished by SJ-172550. (A) Expression 
of human wt p53 and/or human MDMX was confirmed by Western blot analysis; Pgk1p was used as loading control; 
immunoblots are representative of two independent experiments. (B) Effect of 20 µM SJ-172550 on the growth of control 
yeast, yeast expressing only p53 or MDMX and yeast co-expressing p53 and MDMX. Results were plotted setting the 
number of CFU obtained with control yeast incubated with DMSO only as 100% growth. Data are represented as mean ± 
SEM of five independent experiments; significantly different values are indicated (*P < 0.05). (C) Effect of 20 µM 
SJ-172550 on the yeast cell cycle progression of control yeast, yeast expressing only p53 or MDMX and yeast 
co-expressing p53 and MDMX. Datarepresents the mean of two independent experiments. (D, E) Concentration-response 
curves for the reversion of MDMX effect by SJ-172550 in yeast co-expressing p53 (D) and the effects of SJ-172550 on 
the growth of control yeast (empty vectors) and yeast cells expressing p53 alone (E); Yeast cell growth was analysed by 
CFU counts after incubation in the presence of 0.1 – 100 μM SJ-172550 or DMSO only. Data are represented as mean ± 
SEM of four independent experiments; values significantly different from DMSO only (*P < 0.05). 
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3.3. wt p53 interferes with actin protein expression levels in yeast 
In the present work, it was verified that the growth inhibition caused by expression of 
human wt p53 in yeast (Fig. 14A, B; see also Fig. 17) was associated with a marked increase 
of actin protein levels, when compared to control yeast (empty vector) (Fig. 14C). On the 
other hand, the expression in yeast of the p53 R273H mutant (Fig. 14A), which is known for 
its reduced transcriptional activity in comparison to wt p53 both in mammalian cells (Maslon 
and Hupp, 2010) and in a yeast reporter construction (Scharer and Iggo, 1992), caused no 
increase of actin protein levels (Fig. 14C). Accordingly, R273H expression did not interfere 
with yeast cell growth (Fig. 14B; see also Fig. 17) and cell cycle progression (Fig. 18A). 
Interestingly, when the toxic p53 V122A mutant, which has been reported to have higher 
cytotoxic and transcriptional activity than wt p53 (Inga and Resnick, 2001), was expressed 
in yeast (Fig. 14A), its higher inhibitory effect on yeast cell growth (Fig. 14B) was 
accompanied by a higher increase of actin protein levels (Fig. 14D), when compared to wt 
p53.  
 
 
 
 
Fig. 14 – Contrary to R273H, wt p53 and V122A increase actin protein levels. (A) Expression of human wt p53, R273H 
or V122A in yeast was confirmed by Western blot analysis. (B) Effect of wt p53, R273H and V122A on yeast cell growth 
was analysed by CFU counts; results were plotted setting the number of CFU obtained with control yeast (empty vector)  
as 100% growth; data are represented as mean ± SEM of five independent experiments; values significantly different from 
control yeast (*P < 0.05). (C, D) The effect of wt p53, R273H and V122A on actin protein levels was analysed by Western 
blot. Immunoblots represent one of two experiments; Pgk1p was used as loading control. 
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The effect of pifthrin-α (PFT-α), a known inhibitor of the p53 transcriptional activity 
(Gudkov and Komarova, 2005), on the actin expression levels of yeast cells expressing 
wt p53, was also assessed. The results showed that when yeast cells expressing wt p53 
were treated with 20 µM PFT-α, a prominent reduction of p53-induced growth inhibition 
of 41.7 ± 4.3% (n = 4) was observed, as previously reported (Coutinho et al., 2011), 
which was accompanied by a significant reduction of the actin protein levels when 
compared to cells treated with DMSO only (Fig. 15A). 
Since it has been previously shown that MDM2 (Leao et al., 2013) and MDMX 
also inhibited the toxic effect of p53 in yeast, the impact of these two negative regulators 
on p53-induced actin protein levels was also analysed. When co-expressed with wt p53, 
both MDM2 (Fig. 15B) and MDMX (Fig. 15C) led to a visible reduction of actin protein 
levels. Interestingly, the treatment of yeast cells co-expressing p53 and MDM2 with 10 
µM nutlin-3a (the known inhibitor of p53-MDM2 interaction), reverted this inhibitory effect 
of MDM2, re-establishing the p53-induced actin protein levels (Fig. 15B). Similarly to the 
effect of nutlin-3a on MDM2 co-expressing cells, 20 µM SJ-172550 also re-established 
the p53-induced actin protein levels in yeast cells co-expressing p53 and MDMX (Fig. 
15C). Together, these results may suggest that ACT1 (the gene that encodes actin) is 
an endogenous transcriptional target of p53, in yeast.  
 
 
 
 
Fig. 15 – Reduction of actin protein levels by chemical (PFT-α) and natural (MDM2 and MDMX) inhibitors of p53 
activity.  (A) Effect of PFT-α on actin protein levels was analysed by Western blot; yeast cells expressing wt p53 were 
grown in selective induction medium for approximately 30 h in the presence of 20 µM PFT-α or DMSO only. (B) Effect of 
MDM2 on actin protein levels was analysed by Western blot; yeast cells co-expressing human wt p53 and/or MDM2 and 
control yeast (empty vectors) were grown in selective induction medium for approximately 42 h in the presence of 10 µM 
nutlin-3a or DMSO only. (C) Effect of MDMX on actin protein levels was analysed by Western blot; yeast cells 
co-expressing human wt p53 and/or MDMX and control yeast (empty vectors) were grown in selective induction medium 
for approximately 42 h in the presence 20 µM SJ-172550 or DMSO only. Immunoblots are representative of two 
experiments; Pgk1p was used as loading control. 
 
 
 
The effect of p53 on the yeast actin cytoskeleton organization was also assessed 
in this work. For that, yeast cells expressing wt p53 alone were co-transformed with a 
yeast integrative vector encoding the green fluorescent protein (GFP) fused to the actin 
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binding protein 140 (ABP140), as previously described (Sagot et al., 2006). By analysing 
the yeast actin organization by fluorescence microscopy, it was possible to observe that 
wt p53 expression caused a marked actin cytoskeleton depolarization, after 30 h 
incubation in induction selective medium. In fact, contrary to the diffuse GFP cellular 
background corresponding to the staining of actin cables observed in control yeast 
(vector), highly depolarized actin patches confined to regions near the plasma membrane 
could be visualized in a high number of yeast cells expressing wt p53 (Fig. 16B, C).  
 
 
 
 
Fig. 16 – Expression of p53 in yeast induces actin depolarization.  (A) Effect of p53 on yeast actin organization was 
analysed by fluorescence microscopy using yeast expressing wt p53 or control yeast co-transformed with the yeast 
integrative ABP140-3xGFP plasmid, incubated in selective induction medium for 30 h. Bars represent 2 µm. (B) 
Quantification of actin depolarization was estimated by counting at least 300 cells per sample. Data are mean of two 
independent experiments; value significantly different from control yeast (*P < 0.05). 
 
 
 
3.4. Effect of p53 family proteins on yeast cell proliferation and death 
In the present work, the individual expression of the human alpha isoforms of 
p63, ΔNp63 and p73 in yeast was confirmed by Western blot analysis (Fig. 17A). For 
p63α and ΔNp63α, protein bands of 52 and 72 kDa, respectively, were obtained as 
has been previously described for their expression in human cell lines (Kommagani 
et al., 2009). As referred above (in section 3.3), contrary to the p53 R273H mutant 
(used as negative control), the expression of wt p53 in yeast caused a marked yeast 
growth inhibition (Fig. 17B, C). Similarly to wt p53, p63, ΔNp63 and p73 induced yeast 
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growth inhibition (Fig. 17B, C). Nevertheless, with the exception of ΔNp63, the effects 
on yeast cell growth observed with p63 and p73 were different from that observed 
with wt p53 (Fig. 17B, C). In fact, at 30 h incubation, a higher growth inhibitory effect 
was observed with p63, (72.9%) when compared to wt p53 (53.3%) (Fig. 17C). On 
the contrary, a lower growth inhibitory effect was obtained with p73α (40.4%) when 
compared to wt p53 (53.3%) (Fig. 17C). 
 
 
 
 
Fig. 17 – Yeast cell growth inhibition induced by human p53 family members. Yeast cells individually expressing 
human wt p53, R273H, p63, ΔNp63, p73 and control yeast (empty vector) were grown in induction selective medium for 
up to 50 h for growth curves experiments or for 30 h (time required by control yeast to achieve 0.5 OD600) in all other 
experiments. (A) Expression of human wt p53, R273H, p63, ΔNp63 and p73 in yeast was confirmed by Western blot 
analysis. Pgk1p was used as a loading control. Immunoblots are representative of two experiments. (B) Growth curves 
were obtained by CFU counts. Representative data of two independent experiments with six replicates. Values 
significantly different from control yeast (*P < 0.05). (C) Growth inhibition induced by wt p53, R273H, p63, ΔNp63 and 
p73. Results were estimated considering the number of CFU obtained with control yeast as 100%. Results are represented 
as mean ± SEM of six independent experiments. Values significantly different from control yeast (*P < 0.05).  
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Moreover, similarly to wt p53, and contrary to p53 R273H, p63-, ΔNp63- and 
p73-induced growth inhibition was also associated with an arrest in cell cycle 
progression. In fact, both ΔNp63 and p63 induced S-phase cell cycle arrest (22.7% 
for ΔNp63, and 34.4% for p63), similarly to that observed for wt p53 (33.9%) (Fig. 
18). However, a significant increase in the percentage of cells arrested in G1-phase 
(53.3%), instead of S-phase, was observed for p73, when compared to control yeast 
(39.5%) (Fig. 18). Together, the results obtained revealed distinct effects of p53 
family members on the growth and cell cycle progression of yeast cells.  
 
 
 
 
Fig. 18 – Yeast cell cycle arrest induced by human p53 family members. Yeast cells individually expressing human 
wt p53, R273H, p63, ΔNp63, p73 and control yeast (empty vector) were grown in induction selective medium for 30 h; wt 
p53, p63α and ΔNp63α induced S-phase cell cycle arrest and p73 induced G1-phase cell cycle arrest. Mutant p53 R273H 
did not interfere with yeast cell cycle progression. Data are mean ± SEM of two independent experiments; values 
significantly different from control yeast (*P < 0.05).  
 
 
Moreover, the expression of p63, ΔNp63 or p73 in yeast also seemed to 
increase of actin expression levels, when compared to the effect of the empty vector 
(Fig. 19A), as observed for wt p53 (Fig. 14C). This suggested that p63, ΔNp63 and 
p73 may induce the transcription of the ACT1 gene, although possible indirect effects 
cannot be discarded at this stage. 
The effect of p63, ΔNp63 or p73 was also evaluated on yeast actin 
depolarization (Fig. 19B). Similarly to the previously observed for wt p53, p63, ΔNp63 
and p73 significantly increased the percentage of cells with depolarized actin. In spite 
of this, the effects of these p53 family members were not as pronounced as those 
observed with wt p53.  
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Fig. 19 – Effects of p63, ΔNp63, p73 on actin depolarization and protein expression levels. (A) Actin protein levels 
were analysed by Western blot. Pgk1p was used as a loading control. Immunoblots are representative of two independent 
experiments. (B) Quantification of actin depolarization was estimated by counting at least 300 cells per sample; data are 
represented as mean ± SEM of two independent experiments; values significantly different from control yeast (*P < 0.05). 
 
 
 
 
A previous work performed by our group has shown that yeast growth 
inhibition induced by wt p53 was not associated with a necrotic or an apoptotic cell 
death (Coutinho et al., 2009). In the present work, by analysing two cell death 
markers, namely loss of plasma membrane integrity [necrotic cells; PI positively 
stained (PI+) cells], and DNA fragmentation (apoptotic cells; TUNEL positive cells), 
it was verified that, similarly to wt p53, the yeast cell growth inhibition induced by p63, 
ΔNp63, and p73 was not associated with an increase in the percentage of necrotic 
and apoptotic cells, when compared to control yeast (empty vector) (Fig. 20A).  
To further investigate the activity of p53 family proteins on apoptosis, yeast 
cells individually expressing wt p53, p53 R273H, p63, ΔNp63, and p73 and were 
treated with a known yeast apoptotic inducer, H2O2 (Madeo et al., 1999). As 
previously reported for wt p53 (Coutinho et al., 2011), the results obtained in this 
work showed that, upon 1 h treatment with 1.5 and 5 mM H2O2, none of the studied 
p53 family members significantly increased the percentage of H2O2-induced cell 
death, when compared to control yeast (empty vector; Fig. 20B).  
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Fig. 20 – p53 family members do not induce yeast apoptotic cell death. Yeast cells individually expressing human wt 
p53, R273H, p63, p73, ΔNp63 and control yeast (empty vector) were grown in induction selective medium for 30 h. (A) 
Cells with DNA fragmentation (TUNEL +) and necrotic cells (PI +) obtained with yeast cells expressing wt p53, p63, p73, 
ΔNp63 and control yeast . Yeast cells treated with DNAse were used as positive control (C+). Presented are mean ± SEM 
of four independent experiments. (B) Percentage of dead cells obtained with yeast cells expressing wt p53, R273H, p63, 
p73, ΔNp63 and control yeast after treatment with 1.5 or 5 mM H202 for 1 h at 30 ºC. The percentage of dead cells was 
assessed by CFU counts, considering 100% survival (0% death) as the number of CFU obtained with H202-untreated 
cells. Presented are mean ± SEM of four independent experiments. In (A) and (B), values were not significantly different 
from control yeast (vector): P > 0.05. 
 
 
 
The possible involvement of an autophagic process in yeast growth inhibition 
induced by wt p53, p63, ΔNp63 and p73 was then investigated. This was possible by 
using the S. cerevisiae strains wt W303, W303 atg1Δ and W303 atg5Δ individually 
expressing each of these human proteins or the mutant p53 R273H (as negative 
control). The W303 atg1Δ and W303 atg5Δ strains lack atg1p and atg5p, respectively, 
which are proteins required for the autophagosome formation, their deletion leading 
to a defective macroautophagy (George et al., 2000; Kametaka et al., 1996; Matsuura 
et al., 1997). The single expression of wt p53, p53 R273H, p63, ΔNp63, or p73 in 
yeast was confirmed by Western blot analysis (data not shown). Similarly to what was 
observed in the previously described studies (using the CG379 yeast strain), when 
wt p53 was expressed in wt W303 strain, it induced a marked inhibition of yeast 
growth (of approximately 54%), when compared to control yeast (empty vector) (Fig. 
21A). However, a pronounced decrease of wt p53-induced growth inhibition was 
observed when this protein was expressed in W303 atg1Δ (of about 25%) and W303 
atg5Δ (of about 40%) strains (Fig. 21A). On the contrary, R273H did not significantly 
interfere with the yeast cell growth in any of the studied strains (Fig. 21A). Similarly 
to what was observed for wt p53, the p63-, p73- and ΔNp63-induced growth inhibition 
observed in wt W303 strain was also markedly reduced when these proteins were 
expressed in W303 atg1Δ and W303 atg5Δ strains (Fig. 21A): p63 (about 17% for 
atg1Δ and 26% for atg5Δ); p73 (about 36% for atg1Δ and 15% for atg5Δ); ΔNp63 
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about 20% for atg1Δ and 26% for atg5Δ). The difference in the effects observed in 
strains which have mutations in autophagy related genes, when comparing to the wt 
strain seemed to indicate a possible involvement of autophagy in the mechanism of 
action. This was further supported by analysing the expression levels of Atg8p in 
CG379 strain. The expression of Atg8p (a yeast homologue of the mammalian protein 
LC3, one of the proteins required for autophagosome formation) has been shown to 
increase when autophagy is induced (Kirisako et al., 1999). As expected, the results 
indicated that expression of wt p53, p63, ΔNp63 and p73 increased the Atg8p 
expression levels (Fig. 21B). Altogether, these results suggest that the observed 
yeast growth inhibitory effect caused by wt p53, p63, ΔNp63 and p73 could be related 
to an autophagic process. 
In order to clarify whether the growth inhibition induced by p53 family members 
is associated with autophagic cell death, CG379 yeast cells expressing wt p53, p63, 
ΔNp63 or p73 were treated with rapamycin, an inhibitor of mTOR and, therefore, 
inducer of autophagy in yeast (Noda and Ohsumi, 1998), and its effect on yeast cell 
viability was assessed. After 4 h treatment with 0.2 μg/mL rapamycin, it was observed 
that expression of wt p53 in yeast stimulated rapamycin-induced yeast loss of 
viability, when compared to control yeast (Fig. 21C). Although in a lower degree than 
the observed for wt p53, p63, ΔNp63, and p73 also stimulated rapamycin-induced 
yeast loss of viability. Interestingly, contrary to that observed in cell proliferation, no 
differences were observed between the effects obtained with p63, ΔNp63, and p73 
on rapamycin-induced loss of cellular viability.  
These results indicated an involvement of p53 family proteins on an 
autophagic process. Furthermore, the increase of rapamycin-induced yeast loss of 
viability caused by expression of p53 family proteins suggests that the yeast growth 
inhibition induced by these proteins could be related to autophagic death. 
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Fig. 21 – p53 family members induce yeast autophagic cell death. CG379, wt W303, W303 atg1Δ and W303 atg5Δ 
yeast strains individually expressing human wt p53, R273H, p63, p73 or ΔNp63, and control yeast (empty vector) were 
grown in induction selective medium for 30 h (A) Effect of p53 family proteins on wt W303, W303 atg1Δ and W303 atg5Δ 
cell growth was analysed by CFU counts, considering the number of CFU obtained with control yeast as 100%. Results 
are represented as mean ± SEM of four independent experiments; values significantly different from wt W303 (*P < 0.05). 
(B) Atg8p protein levels, in CG379 yeast cells expressing a p53 family protein, were analysed by Western blot. Pgk1p 
was used as a loading control. Immunoblots represent one experiment. Presented in the quantification of immunoblots 
are the values of one experiment. (C) CG379 yeast cells expressing a p53 family protein were treated with 0.2 μg/mL 
rapamycin for 4 h. The percentage of viability was assessed by CFU counts, considering the number of CFU obtained 
with cells incubated with DMSO only as 100%. Presented are mean ± SEM of four independent experiments. Values 
significantly different from control yeast (*P < 0.05). 
 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
53 
 
 
 
Discussion 
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4. Discussion 
4.1. α-Mangostin and gambogic acid as potential inhibitors of the 
p53-MDM2 interaction 
 
α-Mangostin (αMG) and gambogic acid (GA) are naturally occurring 
prenylated xanthones with a well-known potent anti-tumour activity both in vitro 
[reviewed in (Chantarasriwong et al., 2010; Pedraza-Chaverri et al., 2008)], and in 
vivo (Chitchumroonchokchai et al., 2013; Zhao et al., 2008). In spite of this, the 
molecular mechanism of action of these compounds remains controversial. In fact, a 
correlation between their anti-tumour properties and the activation of a 
p53-dependent pathway has been suggested by several authors (Aisha et al., 2012; 
Gu et al., 2008; Rong et al., 2009). Particularly, αMG was shown to increase the p53 
transcriptional activity (Aisha et al., 2012), and to induce apoptosis associated with 
an increase of the protein levels of Bax, a p53 target gene (Kaomongkolgit et al., 
2011). Moreover, it was described that GA induced apoptosis and cell cycle arrest in 
tumour cells expressing wt p53 (Gu et al., 2008). On the other hand, a recent report 
showed that αMG induced apoptosis in a mouse mode l carrying a p53 mutation 
(Shibata et al., 2011). Additionally, it was also shown that GA induced apoptosis and 
cell cycle arrest in human tumour cells lacking p53 (Rong et al., 2009). 
In a previous study, our group identified an inhibitor of the p53-MDM2 
interaction with a xanthone scaffold (Leao et al., 2013). Based on this, it was 
hypothesized that αMG and GA, could also target the p53-MDM2 interaction.  
In the present work, it was shown that, as nutlin-3a, both αMG and GA were 
able to re-establish the p53 activity in yeast by inhibiting the negative effect of MDM2 
on p53. This was consistent with an inhibition of the p53-MDM2 interaction by αMG 
and GA. Furthermore, neither of the xanthones had any effect on the growth of yeast 
cells expressing wt p53 alone, or a mutant form of p53. These results were further 
supported by the fact that studies carried out, under the scope of this work, at Prof. 
Inga’s Lab (Centre for Integrative Biology, CIBIO, University of Trento, Italy), using a 
dual-luciferase yeast p53 transactivation assay [described in (Andreotti et al., 2011)] 
showed that both xanthones (as nutlin-3a) significantly increased the p53 
transcriptional activity by inhibiting the negative effect of MDM2 on p53. Interestingly, 
other studies performed at Prof Inga´s lab have confirmed these results in breast 
adenocarcinoma cell lines and computational studies performed at Prof. Madalena 
Pinto’s Lab (CEQUIMED-UP) suggested that both αMG and GA were able to interact 
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with MDM2. Nevertheless, since those studies were performed by others they were 
not included in this thesis. Together, these results suggested that αMG and GA were 
potential inhibitors of the p53-MDM2 interaction.  
As a whole, the results obtained in this work and by collaborators revealed, 
for the first time, that αMG and GA are potential inhibitors of the p53-MDM2 
interaction. The computational docking studies indicated that, similarly to nutlin-3a, 
αMG and GA have the potential to bind to MDM2, therefore acting as direct inhibitors 
of MDM2. These results provide new clues and open new perspectives into the mode 
of action of these xanthones in human tumour cells with wt p53. Moreover, with the 
confirmation of the results obtained in yeast, a proof-of-concept for the effectiveness 
of the yeast-based assay to search for inhibitors of the p53-MDM2 interaction is 
provided.  
 
 
4.2. Flavonoids as potential activators of p53 
 
Flavonoids represent another group of compounds widely recognized for their 
potent anti-tumour activity (Boumendjel et al., 2009; Lopez-Lazaro, 2002). In general, 
and depending on the cell line studied, the growth inhibitory effects of flavonoids, 
such as 3,7-dihydroxyflavone, have been associated with the induction of cell cycle 
arrest and apoptosis (Monasterio et al., 2004). 
In the present work, five chalcones (a sub-class of flavonoids synthesised by 
the CEQUIMED-UP group) and 3,7-dihydroxyflavone, which had emerged as 
potential p53 activators from a yeast-based screening assay previously performed by 
our group, were tested in human colon carcinoma cell lines with and without p53. As 
expected, all the tested flavonoids presented a potent anti-proliferative activity in both 
cell lines studied. However, no significant differences were observed in the response 
of both cell lines to these flavonoids, which suggested that they had a 
p53-independent mechanism of action. In fact, besides p53, the tested flavonoids 
may probably act on other cellular targets absent in yeast, particularly on another p53 
family protein, such as p73, expressed in both tested tumour cell lines. Therefore, 
additional studies should be performed in order to further investigate the precise 
molecular mechanism of action of these compounds. 
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4.3. Develoment of a yeast model for funtional and pharmacological 
studies of the p53-MDMX interaction 
 
As previously referred, the pharmacological modulation of p53 is a promising 
therapeutic strategy in the treatment of cancer [reviewed in (Chen et al., 2010)]. 
Approximately 50% of all human tumours have wt p53, which is often inactivated 
due to the overexpression of its endogenous negative regulators MDM2 and MDMX 
(Brown et al., 2009). Several efforts have been focused on the therapeutic inhibition 
of the p53-MDM2 interaction, but to date few inhibitors of the p53-MDMX interaction 
have been identified [reviewed in (Zhao et al., 2013)]. Nevertheless, inhibition of 
the p53-MDMX interaction would be particularly useful in the treatment of tumours 
overexpressing MDMX. In fact, MDMX overexpression has been described in 18 – 
19% of breast, lung, and colon cancers (Danovi et al., 2004), 50% of head and neck 
squamous carcinomas (Valentin-Vega et al., 2007), and 65% of retinoblastomas 
(Laurie et al., 2006). Moreover, despite being structurally related proteins with the 
ability to inhibit the p53 transcriptional activity, as referred above, MDM2 and MDMX 
play multifaceted and non-redundant roles in modulating p53. Therefore, the 
development of inhibitors of the interaction both of MDM2 and MDMX with p53 has 
emerged as a promising therapeutic strategy against tumours retaining wt p53 
[reviewed in (Pei et al., 2012; Shadfan et al., 2012; Wade et al., 2013)]. However, 
it has been shown that inhibitors of the p53-MDM2 interaction, such as nutlin-3a, 
were largely ineffective against tumours overexpressing MDMX (Wade and Wahl, 
2009). Recently, Reed and colleagues (2010) identified the first  small molecule 
inhibitor of the p53-MDMX interaction, called SJ-172550. However, its weak cellular 
effect and other limitations for its further development as a selective MDMX inhibitor 
(Bista et al., 2012) have made the need for the discovery of new and more effective  
small molecule inhibitors of the p53-MDMX interaction an urgent area of research. 
Therefore, the development of new screening approaches that may improve and 
expedite this search would certainly contribute to achieve such a goal.  
In the present work, the human p53-MDMX regulatory pathway was 
reconstituted in yeast for the first time. This allowed the development of a simplified 
and cost-effective yeast-based growth inhibition assay, which can be used for the 
screening of potential inhibitors of the p53-MDMX interaction. Additionally, it can be 
easily adapted to the high-throughput screening (HTS) of large chemical libraries, 
since it is based on simple measurements of yeast cell growth by optical density. 
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Overall, the simplified cell model developed under the scope of this thesis 
can be used for functional and molecular studies of the complex p53-MDMX 
network. Most importantly, it can be of great help as a first-line screening of 
potential inhibitors of the p53-MDMX interaction, which may then be tested in more 
complex and physiologically accurate cell models. The use of this assay, in the first 
stage of the drug discovery process, would certainly reduce the costs and expedite 
the identification of new inhibitors of the p53-MDMX interaction. 
 
 
4.4. Development of a simplified yeast p53 transcriptional assay 
based on the identification of a yeast endogenous p53 target 
gene 
 
In a previous work performed in human cells, Comer and colleagues (1998) 
showed that the p53-induced growth inhibition and cell cycle arrest were associated 
with drastic changes in the actin cytoskeleton, and also with an increase of the 
smooth muscle α-actin mRNA levels. More recently, it was also reported that 
nutlin-3a was a potent inducer of smooth muscle α-actin expression in human cells 
(Secchiero et al., 2012). Together, these works showed that actin, with a crucial 
role in cell cycle progression [reviewed in (Heng and Koh, 2010)], was a direct p53 
transcriptional target in human cells.  
In the present work, it was shown that in yeast the p53-induced growth 
inhibition and cell cycle arrest were also associated with an increase of actin protein 
levels, which was modulated by chemical (PFT-α, nutlin-3a and SJ-172550) and 
natural (MDM2 and MDMX) regulators of p53 activity. Furthermore, it was shown 
that in yeast, p53 also induced actin depolarization. These results were further 
supported by studies carried out, under the scope of this work, at Prof. Inga’s Lab, 
in which the actin mRNA levels were determined in yeast cells expressing p53 by 
quantitative-PCR. In accordance with the increase of actin protein levels, a 
significant 2-fold increase of actin mRNA levels was obtained, when compared to 
control yeast. 
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Fig. 22 – Identification of ACT1 as a potential yeast endogenous p53 target gene. (A) Expression of p53 in yeast 
increases the actin protein levels and induces actin depolarization. This effect is reversed by PFT-α, an inhibitor of p53 
transcriptional activity. (B) Co-expression of MDM2 or MDMX inhibits the p53-induced actin protein levels, an effect 
reversed by the inhibitors of the p53-MDM2 and p53-MDMX interactions, nutlin-3a and SJ-172550, respectively.  
 
 
 
Altogether, with this work, relevant insights into the p53 regulatory pathway in 
yeast were revealed. Particularly, the results obtained strongly indicated that ACT1 is a 
potential endogenous p53 transcriptional target in yeast.  
Yeast p53 transactivation assays have been extensively used by several authors 
to study the impact of mutations, cofactors and small molecules on p53 transcriptional 
activity. However, these assays have been carried out using artificial yeast reporter 
constructs with response elements derived from human genes regulated by p53, such 
as PUMA and BAX [reviewed in (Pereira et al., 2012a; Pereira et al., 2012b)]. With the 
identification of ACT1 as a possible endogenous p53 target gene in yeast a new 
simplified and cost-effective yeast p53 transactivation assay may be developed, which 
can be used for the analysis of the p53 transcriptional activity, instead of the traditional 
artificial yeast transactivation reporter assays.  
 
 
4.5. Effect of p53 family proteins on yeast cell proliferation and death 
 
The p53 family proteins regulate several important processes related to cell 
proliferation and death, thus being attractive therapeutic targets in cancer treatment 
[reviewed in (Wei et al., 2012)]. Nevertheless, the molecular and pharmacological profile of 
these proteins remains largely controversial [reviewed in (Vilgelm et al., 2008)]. Furthermore, 
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very few small molecule modulators of p53 family proteins are currently available [reviewed 
in (Chung and Irwin, 2010)].  
The high complexity of the p53 family pathway in mammalian cells led us to the 
development of yeast-based assays to study not only the biology, but also the pharmacology 
of these proteins, particularly to discover isoform-selective p53 family modulators. Therefore, 
in the present work, the p63-, ΔNp63- and p73-signalling networks were reconstituted in 
yeast, and the effects of these p53 family proteins on cell proliferation and death were 
analysed for the first time in yeast.  
The results obtained showed that, in general, although with some differences in the 
intensity of their activities, p53, p63, ΔNp63 and p73 exhibited similar functions in yeast. In 
fact, similarly to p53, the p63, ΔNp63 and p73 proteins were also able to induce yeast growth 
inhibition associated with cell cycle arrest and probably autophagy. Although the stimulation 
of an autophagic cell death by TA isoforms of p63 and p73 had already been described in 
human cells (Eby et al., 2010) this work represents the first report for an induction of 
autophagy by ΔNp63. Further studies are underway, in our laboratory, in order to elucidate 
the cellular localization of p53 family proteins (associated to the induction of an autophagic 
cell death), as well as to identify possible yeast p53 family target genes involved in this 
mechanism. Surprisingly, like p53, none of the tested p53 family proteins interfered with the 
apoptotic cell death in yeast. This may be probably due to the absence of orthologues of 
human p53 target genes involved in apoptosis, particularly Bcl-2 family proteins, such as 
Bax, in yeast. 
Moreover, similarly to p53, the p63, ΔNp63 and p73 proteins increased the actin 
expression levels and induced actin depolarization in yeast cells. In spite of this, the much 
lower degree of actin depolarization observed with p63, ΔNp63 and p73, when compared to 
p53, suggests a lesser involvement of these proteins on actin organization than that of p53. 
Most importantly, to our knowledge, to date, no data is available concerning a possible 
regulation of actin expression by p63, ΔNp63 and p73 in human cells. The results obtained 
in yeast therefore suggest that actin may be regulated by p53 family proteins.  
It has been described that TA isoforms of p63 and p73 are able to induce the 
transcription of p53 target genes in mammalian cells, thus performing similar roles to p53. In 
fact, these proteins are well-known by their anti-proliferative activities in mammalian cells, 
which is consistent with the results obtained in the present work in the yeast model. However, 
since ΔN isoforms lack the N-terminal TAD, it has been proposed that these isoforms are 
transcriptionally inactive (Yang et al., 1998). In fact, ΔN isoforms are generally described as 
dominant-negative regulators of TA isoforms, being often associated with the promotion of 
cell proliferation [reviewed in (Alsafadi et al., 2009)]. Curiously, the present work, showed 
that ΔNp63 induced yeast growth inhibition, similarly to that observed with p53 and with TA 
isoforms of p63 and p73. In agreement with this, similar results were described by Dohn and 
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colleagues (2001), which showed that ΔNp63α could induce apoptosis and cell cycle arrest 
in a p53-null H1299 human carcinoma cell line. The authors also showed that, in these cells, 
ΔNp63α was able to induce the transcription of the p53 target gene CDKN1A (which 
encodes p21), possibly through an alternative transactivation domain. The results obtained 
by Dohn and colleagues (2001) were further confirmed in yeast, suggesting the conservation 
of the ΔNp63α-pathway in this organism. Further studies will be performed in yeast in order 
to clarify the activities of ΔN isoforms.  
As a whole, in the present work, a yeast-based assay was developed for each of the 
p53 family proteins. The independent analysis of the p53 family members in yeast allowed 
the study of the role of each protein in cell proliferation and death with new data on their 
functional and molecular profiles being provided. Further insights about the roles of p53 
family proteins in cellular processes, particularly their involvement in autophagic cell death, 
have emerged from the exploitation of the yeast assays here developed. Additionally, with 
the anti-proliferative effects of p63, ΔNp63 and p73 in yeast, a cell-based phenotypic assay 
was developed, which may be used to study the impact of cofactors (such as MDM2 and 
MDMX) on their activities, as well as to the HTS of selective  small molecule modulators of 
each p53 family member. Finally, with the identification of ACT1 as a possible endogenous 
yeast target gene of p63, ΔNp63 and p73, new simplified and cost-effective yeast 
transactivation assays for the analysis of the transcriptional activity of these p53 family 
proteins may be developed, which can be used instead of the traditional artificial yeast 
transactivation reporter assays. 
 
 
4.6. Final remarks  
 
In the present work, valuable data about the biology and pharmacology of p53 family 
proteins was provided using the yeast model. New targets and pharmacological regulators 
of p53 family proteins were revealed. In addition, new yeast assays were developed, which 
may represent relevant tools for the further elucidation of the p53 family network, as well as 
for the identification of new therapeutic opportunities based on selective modulation of p53 
family proteins.  
The yeast research performed in this thesis confirmed the tremendous potential of 
this model system towards the study of human proteins. It is therefore anticipated that new 
promising discoveries may occur in the area of p53 family proteins using this model 
organism. In fact, as pointed above, new ways were opened and several relevant questions 
were raised with this work, some of them being currently under study in our laboratory, while 
others would be interesting to be investigated in the near future. 
  
FCUP 
Studying p53 family proteins: search for small molecule modulators 
63 
 
 
References 
 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
65 
 
5. References 
Aisha, A.F., K.M. Abu-Salah, Z. Ismail, and A.M. Majid. 2012. In vitro and in vivo anti-
colon cancer effects of Garcinia mangostana xanthones extract. BMC 
Complement Altern Med. 12:104. 
Allocati, N., C. Di Ilio, and V. De Laurenzi. 2012. p63/p73 in the control of cell cycle and 
cell death. Exp Cell Res. 318:1285-1290. 
Alsafadi, S., S. Tourpin, F. Andre, G. Vassal, and J.C. Ahomadegbe. 2009. p53 family: 
at the crossroads in cancer therapy. Curr Med Chem. 16:4328-4344. 
Andreotti, V., Y. Ciribilli, P. Monti, A. Bisio, M. Lion, J. Jordan, G. Fronza, P. Menichini, 
M.A. Resnick, and A. Inga. 2011. p53 transactivation and the impact of mutations, 
cofactors and small molecules using a simplified yeast-based screening system. 
PLoS One. 6:e20643. 
Badciong, J.C., and A.L. Haas. 2002. MdmX is a RING finger ubiquitin ligase capable of 
synergistically enhancing Mdm2 ubiquitination. J Biol Chem. 277:49668-49675. 
Balint, E., S. Bates, and K.H. Vousden. 1999. Mdm2 binds p73 alpha without targeting 
degradation. Oncogene. 18:3923-3929. 
Balint, E., A.C. Phillips, S. Kozlov, C.L. Stewart, and K.H. Vousden. 2002. Induction of 
p57(KIP2) expression by p73beta. Proc Natl Acad Sci U S A. 99:3529-3534. 
Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994. Regulation of mdm2 
expression by p53: alternative promoters produce transcripts with nonidentical 
translation potential. Genes Dev. 8:1739-1749. 
Bista, M., D. Smithson, A. Pecak, G. Salinas, K. Pustelny, J. Min, A. Pirog, K. Finch, M. 
Zdzalik, B. Waddell, B. Wladyka, S. Kedracka-Krok, M.A. Dyer, G. Dubin, and 
R.K. Guy. 2012. On the mechanism of action of SJ-172550 in inhibiting the 
interaction of MDM4 and p53. PLoS One. 7:e37518. 
Böttger, V., A. Böttger, C. Garcia-Echeverria, Y.F. Ramos, A.J.v.d. Eb, A. Jochemsen, 
and D.P. Lane. 1999. Comparative study of the p53-mdm2 and p53-MDMX 
interfaces. Oncogene. 18:189-199. 
Boumendjel, A., X. Ronot, and J. Boutonnat. 2009. Chalcones derivatives acting as cell 
cycle blockers: potential anti cancer drugs? Curr Drug Targets. 10:363-371. 
Brown, C.J., S. Lain, C.S. Verma, A.R. Fersht, and D.P. Lane. 2009. Awakening guardian 
angels: drugging the p53 pathway. Nat Rev Cancer. 9:862-873. 
Bykov, V.J., N. Issaeva, G. Selivanova, and K.G. Wiman. 2002. Mutant p53-dependent 
growth suppression distinguishes PRIMA-1 from known anticancer drugs: a 
statistical analysis of information in the National Cancer Institute database. 
Carcinogenesis. 23:2011-2018. 
Calabro, V., G. Mansueto, T. Parisi, M. Vivo, R.A. Calogero, and G. La Mantia. 2002. 
The human MDM2 oncoprotein increases the transcriptional activity and the 
protein level of the p53 homolog p63. J Biol Chem. 277:2674-2681. 
66 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Chantarasriwong, O., A. Batova, W. Chavasiri, and E.A. Theodorakis. 2010. Chemistry 
and biology of the caged Garcinia xanthones. Chemistry. 16:9944-9962. 
Chen, F., W. Wang, and W.S. El-Deiry. 2010. Current strategies to target p53 in cancer. 
Biochem Pharmacol. 80:724-730. 
Chen, X., L.J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, 
and DNA damage determine the extent of the apoptotic response of tumor cells. 
Genes Dev. 10:2438-2451. 
Chitchumroonchokchai, C., J.M. Thomas-Ahner, J. Li, K.M. Riedl, J. Nontakham, S. 
Suksumrarn, S.K. Clinton, A.D. Kinghorn, and M.L. Failla. 2013. Anti-
tumorigenicity of dietary alpha-mangostin in an HT-29 colon cell xenograft model 
and the tissue distribution of xanthones and their phase II metabolites. Mol Nutr 
Food Res. 57:203-211. 
Chung, J., and M.S. Irwin. 2010. Targeting the p53-family in cancer and 
chemosensitivity: triple threat. Curr Drug Targets. 11:667-681. 
Comer, K.A., P.A. Dennis, L. Armstrong, J.J. Catino, M.B. Kastan, and C.C. Kumar. 
1998. Human smooth muscle alpha-actin gene is a transcriptional target of the 
p53 tumor suppressor protein. Oncogene. 16:1299-1308. 
Costanzo, A., P. Merlo, N. Pediconi, M. Fulco, V. Sartorelli, P.A. Cole, G. Fontemaggi, 
M. Fanciulli, L. Schiltz, G. Blandino, C. Balsano, and M. Levrero. 2002. DNA 
damage-dependent acetylation of p73 dictates the selective activation of 
apoptotic target genes. Mol Cell. 9:175-186. 
Coutinho, I., C. Pereira, G. Pereira, J. Goncalves, M. Corte-Real, and L. Saraiva. 2011. 
Distinct regulation of p53-mediated apoptosis by protein kinase Calpha, delta, 
epsilon and zeta: Evidence in yeast for transcription-dependent and -independent 
p53 apoptotic mechanisms. Exp Cell Res. 317:1147-1158. 
Coutinho, I., G. Pereira, M. Leao, J. Goncalves, M. Corte-Real, and L. Saraiva. 2009. 
Differential regulation of p53 function by protein kinase C isoforms revealed by a 
yeast cell system. FEBS Lett. 583:3582-3588. 
Crighton, D., J. O'Prey, H.S. Bell, and K.M. Ryan. 2007. p73 regulates DRAM-
independent autophagy that does not contribute to programmed cell death. Cell 
Death Differ. 14:1071-1079. 
Danovi, D., E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. 
Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, and 
J.C. Marine. 2004. Amplification of Mdmx (or Mdm4) directly contributes to tumor 
formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 24:5835-
5843. 
Davison, T.S., C. Vagner, M. Kaghad, A. Ayed, D. Caput, and C.H. Arrowsmith. 1999. 
p73 and p63 are homotetramers capable of weak heterotypic interactions with 
each other but not with p53. J Biol Chem. 274:18709-18714. 
Deyoung, M.P., and L.W. Ellisen. 2007. p63 and p73 in human cancer: defining the 
network. Oncogene. 26:5169-5183. 
Di Ventura, B., C. Funaya, C. Antony, M. Knop, and L. Serrano. 2008. Reconstitution of 
Mdm2-dependent post-translational modifications of p53 in yeast. PLoS One. 
3:e1507. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
67 
 
Dohn, M., S. Zhang, and X. Chen. 2001. p63α and ΔNp63α can induce cell cycle arrest 
and apoptosis and differentially regulate p53 target genes. Oncogene. 20:3193-
3205. 
Dolezelova, P., K. Cetkovska, K.H. Vousden, and S. Uldrijan. 2012. Mutational analysis 
of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in 
Mdm2 activity toward p53 and indicates structural differences between Mdm2 
homodimers and Mdm2/MdmX heterodimers. Cell Cycle. 11:953-962. 
Dominguez, G., J.M. Garcia, C. Pena, J. Silva, V. Garcia, L. Martinez, C. Maximiano, 
M.E. Gomez, J.A. Rivera, C. Garcia-Andrade, and F. Bonilla. 2006. DeltaTAp73 
upregulation correlates with poor prognosis in human tumors: putative in vivo 
network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 24:805-815. 
Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, Jr., J.S. 
Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal 
but susceptible to spontaneous tumours. Nature. 356:215-221. 
Dotsch, V., F. Bernassola, D. Coutandin, E. Candi, and G. Melino. 2010. p63 and p73, 
the ancestors of p53. Cold Spring Harb Perspect Biol. 2:a004887. 
Eby, K.G., J.M. Rosenbluth, D.J. Mays, C.B. Marshall, C.E. Barton, S. Sinha, K.N. 
Johnson, L. Tang, and J.A. Pietenpol. 2010. ISG20L1 is a p53 family target gene 
that modulates genotoxic stress-induced autophagy. Mol Cancer. 9:95. 
El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, 
W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator 
of p53 tumor suppression. Cell. 75:817-825. 
Feng, Z., H. Zhang, A.J. Levine, and S. Jin. 2005. The coordinate regulation of the p53 
and mTOR pathways in cells. Proc Natl Acad Sci U S A. 102:8204-8209. 
Fernandez-Salas, E., K.S. Suh, V.V. Speransky, W.L. Bowers, J.M. Levy, T. Adams, 
K.R. Pathak, L.E. Edwards, D.D. Hayes, C. Cheng, A.C. Steven, W.C. Weinberg, 
and S.H. Yuspa. 2002. mtCLIC/CLIC4, an organellular chloride channel protein, 
is increased by DNA damage and participates in the apoptotic response to p53. 
Mol Cell Biol. 22:3610-3620. 
Fields, S., and S.K. Jang. 1990. Presence of a potent transcription activating sequence 
in the p53 protein. Science. 249:1046-1049. 
Flaman, J.M., T. Frebourg, V. Moreau, F. Charbonnier, C. Martin, P. Chappuis, A.P. 
Sappino, I.M. Limacher, L. Bron, J. Benhattar, and et al. 1995. A simple p53 
functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci 
U S A. 92:3963-3967. 
Fleury, C., B. Mignotte, and J.L. Vayssiere. 2002. Mitochondrial reactive oxygen species 
in cell death signaling. Biochimie. 84:131-141. 
Flores, E.R., S. Sengupta, J.B. Miller, J.J. Newman, R. Bronson, D. Crowley, A. Yang, 
F. McKeon, and T. Jacks. 2005. Tumor predisposition in mice mutant for p63 and 
p73: evidence for broader tumor suppressor functions for the p53 family. Cancer 
Cell. 7:363-373. 
Fortin, A., S.P. Cregan, J.G. MacLaurin, N. Kushwaha, E.S. Hickman, C.S. Thompson, 
A. Hakim, P.R. Albert, F. Cecconi, K. Helin, D.S. Park, and R.S. Slack. 2001. 
68 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell 
death. J Cell Biol. 155:207-216. 
Fortuna, M., M.J. Sousa, M. Corte-Real, C. Leao, A. Salvador, and F. Sansonetty. 2001. 
Cell cycle analysis of yeasts. Current protocols in cytometry / editorial board, J. 
Paul Robinson, managing editor ... [et al.]. Chapter 11:Unit 11 13. 
Fritsche, M., C. Haessler, and G. Brandner. 1993. Induction of nuclear accumulation of 
the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:307-
318. 
Fukazawa, T., T. Fujiwara, Y. Morimoto, J. Shao, M. Nishizaki, Y. Kadowaki, A. Hizuta, 
L.B. Owen-Schaub, J.A. Roth, and N. Tanaka. 1999. Differential involvement of 
the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-
type p53 gene transfer in human cancer cells. Oncogene. 18:2189-2199. 
George, M.D., M. Baba, S.V. Scott, N. Mizushima, B.S. Garrison, Y. Ohsumi, and D.J. 
Klionsky. 2000. Apg5p functions in the sequestration step in the cytoplasm-to-
vacuole targeting and macroautophagy pathways. Mol Biol Cell. 11:969-982. 
Gilkes, D.M., Y. Pan, D. Coppola, T. Yeatman, G.W. Reuther, and J. Chen. 2008. 
Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol. 28:1999-
2010. 
Glickman, M.H., and A. Ciechanover. 2002. The ubiquitin-proteasome proteolytic 
pathway: destruction for the sake of construction. Physiol Rev. 82:373-428. 
Gong, J.G., A. Costanzo, H.Q. Yang, G. Melino, W.G. Kaelin, Jr., M. Levrero, and J.Y. 
Wang. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to 
cisplatin-induced DNA damage. Nature. 399:806-809. 
Grob, T.J., U. Novak, C. Maisse, D. Barcaroli, A.U. Luthi, F. Pirnia, B. Hugli, H.U. Graber, 
V. De Laurenzi, M.F. Fey, G. Melino, and A. Tobler. 2001. Human delta Np73 
regulates a dominant negative feedback loop for TAp73 and p53. Cell Death 
Differ. 8:1213-1223. 
Gu, H., X. Wang, S. Rao, J. Wang, J. Zhao, F.L. Ren, R. Mu, Y. Yang, Q. Qi, W. Liu, N. 
Lu, H. Ling, Q. You, and Q. Guo. 2008. Gambogic acid mediates apoptosis as a 
p53 inducer through down-regulation of mdm2 in wild-type p53-expressing 
cancer cells. Mol Cancer Ther. 7:3298-3305. 
Gudkov, A.V., and E.A. Komarova. 2005. Prospective therapeutic applications of p53 
inhibitors. Biochem and Biophys Res Commun. 331:726-736. 
Hadj Amor, I.Y., K. Smaoui, I. Chaabene, I. Mabrouk, L. Djemal, H. Elleuch, M. Allouche, 
R. Mokdad-Gargouri, and A. Gargouri. 2008. Human p53 induces cell death and 
downregulates thioredoxin expression in Saccharomyces cerevisiae. FEMS 
Yeast Res. 8:1254-1262. 
Harmes, D.C., E. Bresnick, E.A. Lubin, J.K. Watson, K.E. Heim, J.C. Curtin, A.M. 
Suskind, J. Lamb, and J. DiRenzo. 2003. Positive and negative regulation of 
deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to 
differential regulation of p53 target genes. Oncogene. 22:7607-7616. 
Harms, K., S. Nozell, and X. Chen. 2004. The common and distinct target genes of the 
p53 family transcription factors. Cell Mol Life Sci. 61:822-842. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
69 
 
Haupt, Y., S. Rowan, E. Shaulian, K.H. Vousden, and M. Oren. 1995. Induction of 
apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9:2170-
2183. 
Heng, Y.W., and C.G. Koh. 2010. Actin cytoskeleton dynamics and the cell division cycle. 
Int J Biochem Cell Biol. 42:1622-1633. 
Hermeking, H., C. Lengauer, K. Polyak, T.C. He, L. Zhang, S. Thiagalingam, K.W. 
Kinzler, and B. Vogelstein. 1997. 14-3-3 sigma is a p53-regulated inhibitor of 
G2/M progression. Mol Cell. 1:3-11. 
Hollstein, M., B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano, and C.C. 
Harris. 1996. Somatic point mutations in the p53 gene of human tumors and cell 
lines: updated compilation. Nucleic Acids Res. 24:141-146. 
Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in 
human cancers. Science. 253:49-53. 
Huang, P.I., J.F. Chang, D.H. Kirn, and T.C. Liu. 2009. Targeted genetic and viral therapy 
for advanced head and neck cancers. Drug Discov Today. 14:570-578. 
Inga, A., and M.A. Resnick. 2001. Novel human p53 mutations that are toxic to yeast can 
enhance transactivation of specific promoters and reactivate tumor p53 mutants. 
Oncogene. 20:3409-3419. 
Ishioka, C., T. Frebourg, Y.X. Yan, M. Vidal, S.H. Friend, S. Schmidt, and R. Iggo. 1993. 
Screening patients for heterozygous p53 mutations using a functional assay in 
yeast. Nat Genet. 5:124-129. 
Issaeva, N., P. Bozko, M. Enge, M. Protopopova, L.G. Verhoef, M. Masucci, A. 
Pramanik, and G. Selivanova. 2004. Small molecule RITA binds to p53, blocks 
p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 10:1321-
1328. 
Ito, H., Y. Fukuda, K. Murata, and A. Kimura. 1983. Transformation of intact yeast cells 
treated with alkali cations. J Bacteriol. 153:163-168. 
Kadakia, M., C. Slader, and S.J. Berberich. 2001. Regulation of p63 function by Mdm2 
and MdmX. DNA Cell Biol. 20:321-330. 
Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J.C. Biscan, A. Valent, A. Minty, P. 
Chalon, J.M. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. 
Monoallelically expressed gene related to p53 at 1p36, a region frequently 
deleted in neuroblastoma and other human cancers. Cell. 90:809-819. 
Kallen, J., A. Goepfert, A. Blechschmidt, A. Izaac, M. Geiser, G. Tavares, P. Ramage, 
P. Furet, K. Masuya, and J. Lisztwan. 2009. Crystal Structures of Human MdmX 
(HdmX) in Complex with p53 Peptide Analogues Reveal Surprising 
Conformational Changes. J Biol Chem. 284:8812-8821. 
Kametaka, S., A. Matsuura, Y. Wada, and Y. Ohsumi. 1996. Structural and functional 
analyses of APG5, a gene involved in autophagy in yeast. Gene. 178:139-143. 
Kaomongkolgit, R., N. Chaisomboon, and P. Pavasant. 2011. Apoptotic effect of alpha-
mangostin on head and neck squamous carcinoma cells. Arch Oral Biol. 56:483-
490. 
70 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Kartasheva, N.N., A. Contente, C. Lenz-Stoppler, J. Roth, and M. Dobbelstein. 2002. 
p53 induces the expression of its antagonist p73 Delta N, establishing an 
autoregulatory feedback loop. Oncogene. 21:4715-4727. 
Kawai, H., D. Wiederschain, and Z.M. Yuan. 2003. Critical contribution of the MDM2 
acidic domain to p53 ubiquitination. Mol Cell Biol. 23:4939-4947. 
Kimura, T., M. Gotoh, Y. Nakamura, and H. Arakawa. 2003. hCDC4b, a regulator of 
cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94:431-436. 
Kirisako, T., M. Baba, N. Ishihara, K. Miyazawa, M. Ohsumi, T. Yoshimori, T. Noda, and 
Y. Ohsumi. 1999. Formation process of autophagosome is traced with 
Apg8/Aut7p in yeast. J Cell Biol. 147:435-446. 
Kishimoto, T., and E. Okumura. 1997. In vivo regulation of the entry into M-phase: initial 
activation and nuclear translocation of cyclin B/Cdc2. Prog Cell Cycle Res. 3:241-
249. 
Kissova, I., M. Deffieu, S. Manon, and N. Camougrand. 2004. Uth1p is involved in the 
autophagic degradation of mitochondria. J Biol Chem. 279:39068-39074. 
Koff, A., A. Giordano, D. Desai, K. Yamashita, J.W. Harper, S. Elledge, T. Nishimoto, 
D.O. Morgan, B.R. Franza, and J.M. Roberts. 1992. Formation and activation of 
a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 
257:1689-1694. 
Kommagani, R., M.K. Leonard, S. Lewis, R.A. Romano, S. Sinha, and M.P. Kadakia. 
2009. Regulation of VDR by deltaNp63alpha is associated with inhibition of cell 
invasion. J Cell Sci. 122:2828-2835. 
Kovalev, S., N. Marchenko, S. Swendeman, M. LaQuaglia, and U.M. Moll. 1998. 
Expression level, allelic origin, and mutation analysis of the p73 gene in 
neuroblastoma tumors and cell lines. Cell Growth Differ. 9:897-903. 
Kovvali, G.K., B. Mehta, C.B. Epstein, and S.G. Lutzker. 2001. Identification of partial 
loss of function p53 gene mutations utilizing a yeast-based functional assay. 
Nucleic Acids Res. 29:E28. 
Krause, K., M. Wasner, W. Reinhard, U. Haugwitz, C.L. Dohna, J. Mossner, and K. 
Engeland. 2000. The tumour suppressor protein p53 can repress transcription of 
cyclin B. Nucleic Acids Res. 28:4410-4418. 
Kravchenko, J.E., G.V. Ilyinskaya, P.G. Komarov, L.S. Agapova, D.V. Kochetkov, E. 
Strom, E.I. Frolova, I. Kovriga, A.V. Gudkov, E. Feinstein, and P.M. Chumakov. 
2008.  small molecule RETRA suppresses mutant p53-bearing cancer cells 
through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 105:6302-
6307. 
Kussie, P.H., S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, and N.P. 
Pavletich. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor 
suppressor transactivation domain. Science. 274:948-953. 
Lane, D.P. 1992. Cancer. p53, guardian of the genome. Nature. 358:15-16. 
Lane, D.P., and L.V. Crawford. 1979. T antigen is bound to a host protein in SV40-
transformed cells. Nature. 278:261-263. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
71 
 
Laurie, N.A., S.L. Donovan, C.S. Shih, J. Zhang, N. Mills, C. Fuller, A. Teunisse, S. Lam, 
Y. Ramos, A. Mohan, D. Johnson, M. Wilson, C. Rodriguez-Galindo, M. Quarto, 
S. Francoz, S.M. Mendrysa, R.K. Guy, J.C. Marine, A.G. Jochemsen, and M.A. 
Dyer. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature. 444:61-
66. 
Leao, M., C. Pereira, A. Bisio, Y. Ciribilli, A.M. Paiva, N. Machado, A. Palmeira, M.X. 
Fernandes, E. Sousa, M. Pinto, A. Inga, and L. Saraiva. 2013. Discovery of a 
new  small molecule inhibitor of p53-MDM2 interaction using a yeast-based 
approach. Biochem Pharmacol. 85:1234-1245. 
Lee, J.T., and W. Gu. 2010. The multiple levels of regulation by p53 ubiquitination. Cell 
Death Differ. 17:86-92. 
Lenos, K., and A.G. Jochemsen. 2011. Functions of MDMX in the modulation of the p53-
response. J Biomed Biotechnol. 2011:876173. 
Li, B., Q. Cheng, Z. Li, and J. Chen. 2010. p53 inactivation by MDM2 and MDMX negative 
feedback loops in testicular germ cell tumors. Cell Cycle. 9:1411-1420. 
Li, H., H. Zhu, C.J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491-501. 
Liedtke, C., N. Groger, M.P. Manns, and C. Trautwein. 2003. The human caspase-8 
promoter sustains basal activity through SP1 and ETS-like transcription factors 
and can be up-regulated by a p53-dependent mechanism. J Biol Chem. 
278:27593-27604. 
Linke, K., P.D. Mace, C.A. Smith, D.L. Vaux, J. Silke, and C.L. Day. 2008. Structure of 
the MDM2/MDMX RING domain heterodimer reveals dimerization is required for 
their ubiquitylation in trans. Cell Death Differ. 15:841-848. 
Linzer, D.I., and A.J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma 
cells. Cell. 17:43-52. 
Little, N.A., and A.G. Jochemsen. 2001. Hdmx and Mdm2 can repress transcription 
activation by p53 but not by p63. Oncogene. 20:4576-4580. 
Liu, G., S. Nozell, H. Xiao, and X. Chen. 2004. DeltaNp73beta is active in transactivation 
and growth suppression. Mol Cell Biol. 24:487-501. 
Lopez-Lazaro, M. 2002. Flavonoids as anticancer agents: structure-activity relationship 
study. Curr Med Chem Anticancer Agents. 2:691-714. 
MacFarlane, M. 2003. TRAIL-induced signalling and apoptosis. Toxicol Lett. 139:89-97. 
MacLachlan, T.K., and W.S. El-Deiry. 2002. Apoptotic threshold is lowered by p53 
transactivation of caspase-6. Proc Natl Acad Sci U S A. 99:9492-9497. 
Madeo, F., E. Frohlich, M. Ligr, M. Grey, S.J. Sigrist, D.H. Wolf, and K.U. Frohlich. 1999. 
Oxygen stress: a regulator of apoptosis in yeast. J Cell Biol. 145:757-767. 
Malkin, D. 1993. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 66:83-
92. 
72 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Manfredi, J.J. 2003. p53 and apoptosis: it's not just in the nucleus anymore. Mol Cell. 
11:552-554. 
Manfredi, J.J. 2010. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an 
oncogene and a tumor suppressor. Genes Dev. 24:1580-1589. 
Marchenko, N.D., S. Wolff, S. Erster, K. Becker, and U.M. Moll. 2007. Monoubiquitylation 
promotes mitochondrial p53 translocation. EMBO J. 26:923-934. 
Marchenko, N.D., A. Zaika, and U.M. Moll. 2000. Death signal-induced localization of 
p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem. 
275:16202-16212. 
Marquez-Valadez, B., R. Lugo-Huitron, V. Valdivia-Cerda, L.R. Miranda-Ramirez, V. 
Perez-De La Cruz, O. Gonzalez-Cuahutencos, I. Rivero-Cruz, R. Mata, A. 
Santamaria, and J. Pedraza-Chaverri. 2009. The natural xanthone alpha-
mangostin reduces oxidative damage in rat brain tissue. Nutr Neurosci. 12:35-
42. 
Martinez, J.D. 2010. Restoring p53 tumor suppressor activity as an anticancer 
therapeutic strategy. Future Oncol. 6:1857-1862. 
Martins, C.P., L. Brown-Swigart, and G.I. Evan. 2006. Modeling the therapeutic efficacy 
of p53 restoration in tumors. Cell. 127:1323-1334. 
Maslon, M.M., and T.R. Hupp. 2010. Drug discovery and mutant p53. Trends Cell Biol. 
20:542-555. 
Matsuura, A., M. Tsukada, Y. Wada, and Y. Ohsumi. 1997. Apg1p, a novel protein kinase 
required for the autophagic process in Saccharomyces cerevisiae. Gene. 
192:245-250. 
Meulmeester, E., R. Frenk, R. Stad, P. de Graaf, J.C. Marine, K.H. Vousden, and A.G. 
Jochemsen. 2003. Critical role for a central part of Mdm2 in the ubiquitylation of 
p53. Mol Cell Biol. 23:4929-4938. 
Mihara, M., S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, and U.M. Moll. 
2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11:577-
590. 
Mills, A.A., B. Zheng, X.J. Wang, H. Vogel, D.R. Roop, and A. Bradley. 1999. p63 is a 
p53 homologue required for limb and epidermal morphogenesis. Nature. 
398:708-713. 
Miyashita, T., and J.C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell. 80:293-299. 
Mizushima, N., B. Levine, A.M. Cuervo, and D.J. Klionsky. 2008. Autophagy fights 
disease through cellular self-digestion. Nature. 451:1069-1075. 
Momand, J., A. Villegas, and V.A. Belyi. 2011. The evolution of MDM2 family genes. 
Gene. 486:23-30. 
Momand, J., G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine. 1992. The mdm-2 
oncogene product forms a complex with the p53 protein and inhibits p53-
mediated transactivation. Cell. 69:1237-1245. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
73 
 
Monasterio, A., M.C. Urdaci, I.V. Pinchuk, N. Lopez-Moratalla, and J.J. Martinez-Irujo. 
2004. Flavonoids induce apoptosis in human leukemia U937 cells through 
caspase-and caspase-calpain-dependent pathways. Nutr Cancer. 50:90-100. 
Monks, A., D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. 
Langley, P. Cronise, A. Vaigro-Wolff, and et al. 1991. Feasibility of a high-flux 
anticancer drug screen using a diverse panel of cultured human tumor cell lines. 
J Natl Cancer Inst. 83:757-766. 
Morgan, D.O. 1995. Principles of CDK regulation. Nature. 374:131-134. 
Nakagawa, T., M. Takahashi, T. Ozaki, K. Watanabe Ki, S. Todo, H. Mizuguchi, T. 
Hayakawa, and A. Nakagawara. 2002. Autoinhibitory regulation of p73 by Delta 
Np73 to modulate cell survival and death through a p73-specific target element 
within the Delta Np73 promoter. Mol Cell Biol. 22:2575-2585. 
Nakano, K., and K.H. Vousden. 2001. PUMA, a novel proapoptotic gene, is induced by 
p53. Mol Cell. 7:683-694. 
Neves, M.P., S. Cravo, R.T. Lima, M.H. Vasconcelos, M.S. Nascimento, A.M. Silva, M. 
Pinto, H. Cidade, and A.G. Correa. 2012a. Solid-phase synthesis of 2'-
hydroxychalcones. Effects on cell growth inhibition, cell cycle and apoptosis of 
human tumor cell lines. Bioorg Med Chem. 20:25-33. 
Neves, M.P., R.T. Lima, K. Choosang, P. Pakkong, M. de Sao Jose Nascimento, M.H. 
Vasconcelos, M. Pinto, A.M. Silva, and H. Cidade. 2012b. Synthesis of a natural 
chalcone and its prenyl analogs--evaluation of tumor cell growth-inhibitory 
activities, and effects on cell cycle and apoptosis. Chem Biodivers. 9:1133-1143. 
Newmeyer, D.D., and S. Ferguson-Miller. 2003. Mitochondria: releasing power for life 
and unleashing the machineries of death. Cell. 112:481-490. 
Nigro, J.M., R. Sikorski, S.I. Reed, and B. Vogelstein. 1992. Human p53 and CDC2Hs 
genes combine to inhibit the proliferation of Saccharomyces cerevisiae. Mol Cell 
Biol. 12:1357-1365. 
Noda, T., and Y. Ohsumi. 1998. Tor, a phosphatidylinositol kinase homologue, controls 
autophagy in yeast. J Biol Chem. 273:3963-3966. 
Nurse, P. 2000. A long twentieth century of the cell cycle and beyond. Cell. 100:71-78. 
Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. 
Taniguchi, and N. Tanaka. 2000a. Noxa, a BH3-only member of the Bcl-2 family 
and candidate mediator of p53-induced apoptosis. Science. 288:1053-1058. 
Oda, K., H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. 
Tamai, T. Tokino, Y. Nakamura, and Y. Taya. 2000b. p53AIP1, a potential 
mediator of p53-dependent apoptosis, and its regulation by Ser-46-
phosphorylated p53. Cell. 102:849-862. 
Ohki, R., J. Nemoto, H. Murasawa, E. Oda, J. Inazawa, N. Tanaka, and T. Taniguchi. 
2000. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest 
at the G2 phase. J Biol Chem. 275:22627-22630. 
Olsson, A., C. Manzl, A. Strasser, and A. Villunger. 2007. How important are post-
translational modifications in p53 for selectivity in target-gene transcription and 
tumour suppression? Cell Death Differ. 14:1561-1575. 
74 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Ongkeko, W.M., X.Q. Wang, W.Y. Siu, A.W. Lau, K. Yamashita, A.L. Harris, L.S. Cox, 
and R.Y. Poon. 1999. MDM2 and MDMX bind and stabilize the p53-related 
protein p73. Curr Biol. 9:829-832. 
Owen-Schaub, L.B., W. Zhang, J.C. Cusack, L.S. Angelo, S.M. Santee, T. Fujiwara, J.A. 
Roth, A.B. Deisseroth, W.W. Zhang, E. Kruzel, and et al. 1995. Wild-type human 
p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell 
Biol. 15:3032-3040. 
Park, B.J., S.J. Lee, J.I. Kim, S.J. Lee, C.H. Lee, S.G. Chang, J.H. Park, and S.G. Chi. 
2000. Frequent alteration of p63 expression in human primary bladder 
carcinomas. Cancer Res. 60:3370-3374. 
Pedraza-Chaverri, J., N. Cardenas-Rodriguez, M. Orozco-Ibarra, and J.M. Perez-Rojas. 
2008. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem 
Toxicol. 46:3227-3239. 
Pei, D., Y. Zhang, and J. Zheng. 2012. Regulation of p53: a collaboration between Mdm2 
and Mdmx. Oncotarget. 3:228-235. 
Pereira, C., I. Coutinho, J. Soares, C. Bessa, M. Leao, and L. Saraiva. 2012a. New 
insights into cancer-related proteins provided by the yeast model. FEBS J. 
279:697-712. 
Pereira, C., M. Leao, J. Soares, C. Bessa, and L. Saraiva. 2012b. New therapeutic 
strategies for cancer and neurodegeneration emerging from yeast cell-based 
systems. Curr Pharm Des. 18:4223-4235. 
Perez, C.A., J. Ott, D.J. Mays, and J.A. Pietenpol. 2007. p63 consensus DNA-binding 
site: identification, analysis and application into a p63MH algorithm. Oncogene. 
26:7363-7370. 
Petre-Lazar, B., G. Livera, S.G. Moreno, E. Trautmann, C. Duquenne, V. Hanoux, R. 
Habert, and H. Coffigny. 2007. The role of p63 in germ cell apoptosis in the 
developing testis. J Cell Physiol. 210:87-98. 
Phillips, A., A. Teunisse, S. Lam, K. Lodder, M. Darley, M. Emaduddin, A. Wolf, J. 
Richter, J. de Lange, M. Verlaan-de Vries, K. Lenos, A. Bohnke, F. Bartel, J.P. 
Blaydes, and A.G. Jochemsen. 2010. HDMX-L is expressed from a functional 
p53-responsive promoter in the first intron of the HDMX gene and participates in 
an autoregulatory feedback loop to control p53 activity. J Biol Chem. 285:29111-
29127. 
Popowicz, G.M., A. Czarna, U. Rothweiler, A. Szwagierczak, M. Krajewski, L. Weber, 
and T.A. Holak. 2007. Molecular basis for the inhibition of p53 by Mdmx. Cell 
Cycle. 6:2386-2392. 
Reed, D., Y. Shen, A.A. Shelat, L.A. Arnold, A.M. Ferreira, F. Zhu, N. Mills, D.C. 
Smithson, C.A. Regni, D. Bashford, S.A. Cicero, B.A. Schulman, A.G. 
Jochemsen, R.K. Guy, and M.A. Dyer. 2010. Identification and characterization 
of the first small molecule inhibitor of MDMX. J Biol Chem. 285:10786-10796. 
Reinhardt, H.C., and B. Schumacher. 2012. The p53 network: cellular and systemic DNA 
damage responses in aging and cancer. Trends Genet. 28:128-136. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
75 
 
Ries, S., C. Biederer, D. Woods, O. Shifman, S. Shirasawa, T. Sasazuki, M. McMahon, 
M. Oren, and F. McCormick. 2000. Opposing effects of Ras on p53: 
transcriptional activation of mdm2 and induction of p19ARF. Cell. 103:321-330. 
Rippin, T.M., V.J. Bykov, S.M. Freund, G. Selivanova, K.G. Wiman, and A.R. Fersht. 
2002. Characterization of the p53-rescue drug CP-31398 in vitro and in living 
cells. Oncogene. 21:2119-2129. 
Rong, J.J., R. Hu, Q. Qi, H.Y. Gu, Q. Zhao, J. Wang, R. Mu, Q.D. You, and Q.L. Guo. 
2009. Gambogic acid down-regulates MDM2 oncogene and induces 
p21(Waf1/CIP1) expression independent of p53. Cancer Lett. 284:102-112. 
Rutkowski, R., K. Hofmann, and A. Gartner. 2010. Phylogeny and function of the 
invertebrate p53 superfamily. Cold Spring Harb Perspect Biol. 2:a001131. 
Ryan, K.M. 2011. p53 and autophagy in cancer: guardian of the genome meets guardian 
of the proteome. Eur J Cancer. 47:44-50. 
Sagot, I., B. Pinson, B. Salin, and B. Daignan-Fornier. 2006. Actin bodies in yeast 
quiescent cells: an immediately available actin reserve? Mol Biol Cell. 17:4645-
4655. 
Saraiva, L., R.D. Silva, G. Pereira, J. Goncalves, and M. Corte-Real. 2006. Specific 
modulation of apoptosis and Bcl-xL phosphorylation in yeast by distinct 
mammalian protein kinase C isoforms. J Cell Sci. 119:3171-3181. 
Sax, J.K., P. Fei, M.E. Murphy, E. Bernhard, S.J. Korsmeyer, and W.S. El-Deiry. 2002. 
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 4:842-849. 
Sayan, A.E., J.P. Roperch, B.S. Sayan, M. Rossi, M.J. Pinkoski, R.A. Knight, A.E. Willis, 
and G. Melino. 2007. Generation of DeltaTAp73 proteins by translation from a 
putative internal ribosome entry site. Ann N Y Acad Sci. 1095:315-324. 
Scharer, E., and R. Iggo. 1992. Mammalian p53 can function as a transcription factor in 
yeast. Nucleic Acids Res. 20:1539-1545. 
Secchiero, P., E. Rimondi, M.G. di Iasio, R. Voltan, A. Gonelli, and G. Zauli. 2012. 
Activation of the p53 pathway induces alpha-smooth muscle actin expression in 
both myeloid leukemic cells and normal macrophages. J Cell Physiol. 227:1829-
1837. 
Seo, Y.W., J.N. Shin, K.H. Ko, J.H. Cha, J.Y. Park, B.R. Lee, C.W. Yun, Y.M. Kim, D.W. 
Seol, D.W. Kim, X.M. Yin, and T.H. Kim. 2003. The molecular mechanism of 
Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J Biol Chem. 
278:48292-48299. 
Serber, Z., H.C. Lai, A. Yang, H.D. Ou, M.S. Sigal, A.E. Kelly, B.D. Darimont, P.H. Duijf, 
H. Van Bokhoven, F. McKeon, and V. Dotsch. 2002. A C-terminal inhibitory 
domain controls the activity of p63 by an intramolecular mechanism. Mol Cell 
Biol. 22:8601-8611. 
Shadfan, M., V. Lopez-Pajares, and Z.M. Yuan. 2012. MDM2 and MDMX: Alone and 
together in regulation of p53. Transl Cancer Res. 1:88-89. 
Shangary, S., and S. Wang. 2009.  small molecule inhibitors of the MDM2-p53 protein-
protein interaction to reactivate p53 function: a novel approach for cancer 
therapy. Annu Rev Pharmacol Toxicol. 49:223-241. 
76 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Shibata, M.A., M. Iinuma, J. Morimoto, H. Kurose, K. Akamatsu, Y. Okuno, Y. Akao, and 
Y. Otsuki. 2011. alpha-Mangostin extracted from the pericarp of the mangosteen 
(Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis 
in an immunocompetent xenograft model of metastatic mammary cancer carrying 
a p53 mutation. BMC Med. 9:69. 
Smardova, J., J. Smarda, and J. Koptikova. 2005. Functional analysis of p53 tumor 
suppressor in yeast. Differentiation. 73:261-277. 
Smits, V.A., R. Klompmaker, T. Vallenius, G. Rijksen, T.P. Makela, and R.H. Medema. 
2000. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA 
damage checkpoint. J Biol Chem. 275:30638-30643. 
Sniezek, J.C., K.E. Matheny, M.D. Westfall, and J.A. Pietenpol. 2004. Dominant negative 
p63 isoform expression in head and neck squamous cell carcinoma. 
Laryngoscope. 114:2063-2072. 
Stevens, C., and N.B. La Thangue. 2003. E2F and cell cycle control: a double-edged 
sword. Arch Biochem Biophys. 412:157-169. 
Stiewe, T., C.C. Theseling, and B.M. Putzer. 2002. Transactivation-deficient Delta TA-
p73 inhibits p53 by direct competition for DNA binding: implications for 
tumorigenesis. J Biol Chem. 277:14177-14185. 
Sugars, K.L., V. Budhram-Mahadeo, G. Packham, and D.S. Latchman. 2001. A minimal 
Bcl-x promoter is activated by Brn-3a and repressed by p53. Nucleic Acids Res. 
29:4530-4540. 
Sui, X., L. Jin, X. Huang, S. Geng, C. He, and X. Hu. 2011. p53 signaling and autophagy 
in cancer: a revolutionary strategy could be developed for cancer treatment. 
Autophagy. 7:565-571. 
Takimoto, R., and W.S. El-Deiry. 2000. Wild-type p53 transactivates the KILLER/DR5 
gene through an intronic sequence-specific DNA-binding site. Oncogene. 
19:1735-1743. 
Tasdemir, E., M. Chiara Maiuri, E. Morselli, A. Criollo, M. D'Amelio, M. Djavaheri-Mergny, 
F. Cecconi, N. Tavernarakis, and G. Kroemer. 2008. A dual role of p53 in the 
control of autophagy. Autophagy. 4:810-814. 
Taylor, W.R., A.H. Schonthal, J. Galante, and G.R. Stark. 2001. p130/E2F4 binds to and 
represses the cdc2 promoter in response to p53. J Biol Chem. 276:1998-2006. 
Thanos, C.D., and J.U. Bowie. 1999. p53 Family members p63 and p73 are SAM 
domain-containing proteins. Protein Sci. 8:1708-1710. 
Tomasini, R., K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, C.C. Cheung, F. Khan, 
A. Itie-Youten, A. Wakeham, M.S. Tsao, J.L. Iovanna, J. Squire, I. Jurisica, D. 
Kaplan, G. Melino, A. Jurisicova, and T.W. Mak. 2008. TAp73 knockout shows 
genomic instability with infertility and tumor suppressor functions. Genes Dev. 
22:2677-2691. 
Tomkova, K., W. El-Rifai, A. Vilgelm, M.C. Kelly, T.C. Wang, and A.I. Zaika. 2006. The 
gastrin gene promoter is regulated by p73 isoforms in tumor cells. Oncogene. 
25:6032-6036. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
77 
 
Uldrijan, S., W.J. Pannekoek, and K.H. Vousden. 2007. An essential function of the 
extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 26:102-112. 
Urist, M.J., C.J. Di Como, M.L. Lu, E. Charytonowicz, D. Verbel, C.P. Crum, T.A. Ince, 
F.D. McKeon, and C. Cordon-Cardo. 2002. Loss of p63 expression is associated 
with tumor progression in bladder cancer. Am J Pathol. 161:1199-1206. 
Utrera, R., L. Collavin, D. Lazarevic, D. Delia, and C. Schneider. 1998. A novel p53-
inducible gene coding for a microtubule-localized protein with G2-phase-specific 
expression. EMBO J. 17:5015-5025. 
Valentin-Vega, Y.A., J.A. Barboza, G.P. Chau, A.K. El-Naggar, and G. Lozano. 2007. 
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. 
Hum Pathol. 38:1553-1562. 
van Bokhoven, H., and H.G. Brunner. 2002. Splitting p63. Am J Hum Genet. 71:1-13. 
Vassilev, L.T. 2004.  small molecule antagonists of p53-MDM2 binding: research tools 
and potential therapeutics. Cell Cycle. 3:419-421. 
Vassilev, L.T., B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. 
Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E.A. Liu. 2004. In vivo activation 
of the p53 pathway by  small molecule antagonists of MDM2. Science. 303:844-
848. 
Ventura, A., D.G. Kirsch, M.E. McLaughlin, D.A. Tuveson, J. Grimm, L. Lintault, J. 
Newman, E.E. Reczek, R. Weissleder, and T. Jacks. 2007. Restoration of p53 
function leads to tumour regression in vivo. Nature. 445:661-665. 
Vichai, V., and K. Kirtikara. 2006. Sulforhodamine B colorimetric assay for cytotoxicity 
screening. Nat Protoc. 1:1112-1116. 
Vikhanskaya, F., W.H. Toh, I. Dulloo, Q. Wu, L. Boominathan, H.H. Ng, K.H. Vousden, 
and K. Sabapathy. 2007. p73 supports cellular growth through c-Jun-dependent 
AP-1 transactivation. Nat Cell Biol. 9:698-705. 
Vilgelm, A., W. El-Rifai, and A. Zaika. 2008. Therapeutic prospects for p73 and p63: 
rising from the shadow of p53. Drug Resist Updat. 11:152-163. 
Wade, M., Y.C. Li, and G.M. Wahl. 2013. MDM2, MDMX and p53 in oncogenesis and 
cancer therapy. Nat Rev Cancer. 13:83-96. 
Wade, M., and G.M. Wahl. 2009. Targeting Mdm2 and Mdmx in cancer therapy: better 
living through medicinal chemistry? Mol Cancer Res : MCR. 7:1-11. 
Wade, M., Y.V. Wang, and G.M. Wahl. 2010. The p53 orchestra: Mdm2 and Mdmx set 
the tone. Trends Cell Biol. 20:299-309. 
Wager, M., J. Guilhot, J.L. Blanc, S. Ferrand, S. Milin, B. Bataille, F. Lapierre, S. Denis, 
T. Chantereau, C.J. Larsen, and L. Karayan-Tapon. 2006. Prognostic value of 
increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma 
patients. Br J Cancer. 95:1062-1069. 
Wang, W., R. Takimoto, F. Rastinejad, and W.S. El-Deiry. 2003. Stabilization of p53 by 
CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 
20 or MDM2 binding. Mol Cell Biol. 23:2171-2181. 
78 FCUP 
Studying p53 family proteins: search for small molecule modulators 
 
Wang, X., T. Arooz, W.Y. Siu, C.H.S. Chiu, A. Lau, K. Yamashita, and R.Y.C. Poon. 
2001. MDM2 and MDMX can interact differently with ARF and members of the 
p53 family. FEBS Lett. 490:202-208. 
Weber, A., U. Bellmann, F. Bootz, C. Wittekind, and A. Tannapfel. 2002. Expression of 
p53 and its homologues in primary and recurrent squamous cell carcinomas of 
the head and neck. Int J Cancer. 99:22-28. 
Wei, C.L., Q. Wu, V.B. Vega, K.P. Chiu, P. Ng, T. Zhang, A. Shahab, H.C. Yong, Y. Fu, 
Z. Weng, J. Liu, X.D. Zhao, J.L. Chew, Y.L. Lee, V.A. Kuznetsov, W.K. Sung, 
L.D. Miller, B. Lim, E.T. Liu, Q. Yu, H.H. Ng, and Y. Ruan. 2006. A global map of 
p53 transcription-factor binding sites in the human genome. Cell. 124:207-219. 
Wei, J., E. Zaika, and A. Zaika. 2012. p53 Family: Role of Protein Isoforms in Human 
Cancer. J Nucleic Acids. 2012:687359. 
Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-
330. 
Wilhelm, M.T., A. Rufini, M.K. Wetzel, K. Tsuchihara, S. Inoue, R. Tomasini, A. Itie-
Youten, A. Wakeham, M. Arsenian-Henriksson, G. Melino, D.R. Kaplan, F.D. 
Miller, and T.W. Mak. 2010. Isoform-specific p73 knockout mice reveal a novel 
role for delta Np73 in the DNA damage response pathway. Genes Dev. 24:549-
560. 
Wu, G., S. Nomoto, M.O. Hoque, T. Dracheva, M. Osada, C.C. Lee, S.M. Dong, Z. Guo, 
N. Benoit, Y. Cohen, P. Rechthand, J. Califano, C.S. Moon, E. Ratovitski, J. Jen, 
D. Sidransky, and B. Trink. 2003. DeltaNp63alpha and TAp63alpha regulate 
transcription of genes with distinct biological functions in cancer and 
development. Cancer Res. 63:2351-2357. 
Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53-mdm-2 autoregulatory 
feedback loop. Genes Dev. 7:1126-1132. 
Xue, W., L. Zender, C. Miething, R.A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-
Cardo, and S.W. Lowe. 2007. Senescence and tumour clearance is triggered by 
p53 restoration in murine liver carcinomas. Nature. 445:656-660. 
Yang, A., M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, V. Dotsch, N.C. Andrews, D. 
Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple 
products with transactivating, death-inducing, and dominant-negative activities. 
Mol Cell. 2:305-316. 
Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. 
Bonnet, P. Dikkes, A. Sharpe, F. McKeon, and D. Caput. 2000. p73-deficient 
mice have neurological, pheromonal and inflammatory defects but lack 
spontaneous tumours. Nature. 404:99-103. 
Yang, Z., and D.J. Klionsky. 2010. Mammalian autophagy: core molecular machinery 
and signaling regulation. Curr Opin Cell Biol. 22:124-131. 
Yorimitsu, T., S. Zaman, J.R. Broach, and D.J. Klionsky. 2007. Protein kinase A and 
Sch9 cooperatively regulate induction of autophagy in Saccharomyces 
cerevisiae. Mol Biol Cell. 18:4180-4189. 
FCUP 
Studying p53 family proteins: search for small molecule modulators 
79 
 
Yousef, A.F., G.W. Xu, M. Mendez, C.J. Brandl, and J.S. Mymryk. 2008. Coactivator 
requirements for p53-dependent transcription in the yeast Saccharomyces 
cerevisiae. Int J Cancer. 122:942-946. 
Yu, J., L. Zhang, P.M. Hwang, K.W. Kinzler, and B. Vogelstein. 2001. PUMA induces the 
rapid apoptosis of colorectal cancer cells. Mol Cell. 7:673-682. 
Yuan, Z.M., H. Shioya, T. Ishiko, X. Sun, J. Gu, Y.Y. Huang, H. Lu, S. Kharbanda, R. 
Weichselbaum, and D. Kufe. 1999. p73 is regulated by tyrosine kinase c-Abl in 
the apoptotic response to DNA damage. Nature. 399:814-817. 
Yun, J., H.D. Chae, H.E. Choy, J. Chung, H.S. Yoo, M.H. Han, and D.Y. Shin. 1999. p53 
negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription 
factor. J Biol Chem. 274:29677-29682. 
Zaika, A.I., N. Slade, S.H. Erster, C. Sansome, T.W. Joseph, M. Pearl, E. Chalas, and 
U.M. Moll. 2002. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and 
TAp73, is up-regulated in human tumors. J Exp Med. 196:765-780. 
Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-
responsive intronic promoter is contained within the human mdm2 gene. Nucleic 
Acids Res. 23:2584-2592. 
Zdzalik, M., K. Pustelny, S. Kedracka-Krok, K. Huben, A. Pecak, B. Wladyka, S. 
Jankowski, A. Dubin, J. Potempa, and G. Dubin. 2010. Interaction of regulators 
Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle. 9:4584-
4591. 
Zeng, X., L. Chen, C.A. Jost, R. Maya, D. Keller, X. Wang, W.G. Kaelin, Jr., M. Oren, J. 
Chen, and H. Lu. 1999. MDM2 suppresses p73 function without promoting p73 
degradation. Mol Cell Biol. 19:3257-3266. 
Zetterberg, A., O. Larsson, and K.G. Wiman. 1995. What is the restriction point? Curr 
Opin Cell Biol. 7:835-842. 
Zha, J., S. Weiler, K.J. Oh, M.C. Wei, and S.J. Korsmeyer. 2000. Posttranslational N-
myristoylation of BID as a molecular switch for targeting mitochondria and 
apoptosis. Science. 290:1761-1765. 
Zhan, Q., M.J. Antinore, X.W. Wang, F. Carrier, M.L. Smith, C.C. Harris, and A.J. 
Fornace, Jr. 1999. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase 
activity by the p53-regulated protein Gadd45. Oncogene. 18:2892-2900. 
Zhao, J., Q. Qi, Y. Yang, H.Y. Gu, N. Lu, W. Liu, W. Wang, L. Qiang, L.B. Zhang, Q.D. 
You, and Q.L. Guo. 2008. Inhibition of alpha(4) integrin mediated adhesion was 
involved in the reduction of B16-F10 melanoma cells lung colonization in 
C57BL/6 mice treated with gambogic acid. Eur J Pharmacol. 589:127-131. 
Zhao, Y., D. Bernard, and S. Wang. 2013. Small Molecule Inhibitors of MDM2-p53 and 
MDMX-p53 Interactions as New Cancer Therapeutics. BioDiscovery. 8:4. 
Zhu, J., and X. Chen. 2000. MCG10, a novel p53 target gene that encodes a KH domain 
RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in 
G(2)-M. Mol Cell Biol. 20:5602-5618. 
